Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-11-212464.txt : 20110805 0001193125-11-212464.hdr.sgml : 20110805 20110805165232 ACCESSION NUMBER: 0001193125-11-212464 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110805 DATE AS OF CHANGE: 20110805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 111014810 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 10-Q 1 d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

¨	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-20584

ABIOMED, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

04-2743260

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

22 CHERRY HILL DRIVE

DANVERS, MASSACHUSETTS 01923

(Address of principal executive offices, including zip code)

(978) 646-1400

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is, a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of July 31, 2011, there were 38,523,668 shares outstanding of the registrant’s Common Stock, $.01 par value.

ABIOMED, INC. AND SUBSIDIARIES

TABLE OF CONTENTS


		Page

PART I - FINANCIAL INFORMATION:			3

Item 1.	Financial Statements		3

	Consolidated Balance Sheets as of June 30, 2011 (unaudited) and March 31, 2011		3

	Consolidated Statements of Operations for the three months ended June 30, 2011 and 2010 (unaudited)		4

	Consolidated Statements of Cash Flows for the three months ended June 30, 2011 and 2010 (unaudited)		5

	Notes to Consolidated Financial Statements (unaudited)		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		19

Item 4.	Controls and Procedures		20

PART II - OTHER INFORMATION			20

Item 1.	Legal Proceedings		20

Item 1A.	Risk Factors		20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		20

Item 3.	Defaults Upon Senior Securities		20

Item 4.	(Removed and Reserved)		20

Item 5.	Other Information		20

Item 6.	Exhibits		21

SIGNATURES			22

ABIOMED and ABIOCOR are trademarks of ABIOMED, Inc., and are registered in the United States and certain foreign countries. BVS is a trademark of ABIOMED, Inc. and is registered in the United States. AB5000 is a trademark of ABIOMED, Inc. IMPELLA and RECOVER are trademarks of Abiomed Europe GmbH, a subsidiary of ABIOMED, Inc., and are registered in the United States and certain foreign countries.

PART 1. FINANCIAL INFORMATION

ITEM 1:

FINANCIAL STATEMENTS

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)


	June 30, 2011			March 31, 2011
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,151		$	5,831
Short-term marketable securities		54,982			54,481
Accounts receivable, net		14,541			15,376
Inventories		8,879			7,505
Prepaid expenses and other current assets		1,339			1,544

Total current assets		83,892			84,737
Property and equipment, net		6,214			6,273
Intangible assets, net		1,279			1,632
Goodwill		39,752			38,946

Total assets	$	131,137		$	131,588

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	4,964		$	6,283
Accrued expenses		8,700			14,078
Deferred revenue		1,715			1,982

Total current liabilities		15,379			22,343
Long-term deferred tax liability		4,106			4,010
Other long-term liabilities		469			492

Total liabilities		19,954			26,845


Commitments and contingencies (Note 9)

Stockholders’ equity:
Class B Preferred Stock, $.01 par value		—			—
Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value		385			377
Authorized - 100,000,000 shares; Issued - 38,560,747 shares at June 30, 2011 and 37,756,719 shares at March 31, 2011;
Outstanding - 38,509,793 shares at June 30, 2011 and 37,705,765 shares at March 31, 2011
Additional paid-in-capital		389,217			379,218
Accumulated deficit		(279,364	)		(274,770	)
Treasury stock at cost - 50,954 shares		(827	)		(827	)
Accumulated other comprehensive income		1,772			745

Total stockholders’ equity		111,183			104,743

Total liabilities and stockholders’ equity	$	131,137		$	131,588

See Accompanying Notes to Consolidated Financial Statements (Unaudited).

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)


	Three Months Ended June 30,
	2011			2010
Revenue:
Products	$	27,166		$	21,761
Funded research and development		189			241

		27,355			22,002

Costs and expenses:
Cost of product revenue excluding amortization of intangibles		5,891			5,284
Research and development		7,324			6,653
Selling, general and administrative		18,176			15,753
Amortization of intangible assets		385			367

		31,776			28,057

Loss from operations		(4,421	)		(6,055	)

Other (expense) income :
Investment income (expense), net		4			(2	)
Gain on sale of WorldHeart stock		—			239
Other (expense) income, net		(81	)		81

		(77	)		318

Loss before provision for income taxes		(4,498	)		(5,737	)
Provision for income taxes		96			243

Net loss	$	(4,594	)	$	(5,980	)


Basic and diluted net loss per share	$	(0.12	)	$	(0.16	)
Weighted average shares outstanding		38,268			37,086

See Accompanying Notes to Consolidated Financial Statements (Unaudited).

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Three months ended June 30,
	2011			2010
Operating activities:
Net loss	$	(4,594	)	$	(5,980	)
Adjustments required to reconcile net loss to net cash used for operating activities:
Depreciation and amortization		1,046			959
Bad debt expense		15			53
Stock-based compensation		2,332			1,371
Write-down of inventory		156			623
Loss on disposal of fixed assets		—			5
Deferred tax provision		96			243
Gain on sale of WorldHeart common stock		—			(239	)
Changes in assets and liabilities source (use):
Accounts receivable		847			767
Inventories		(1,601	)		645
Prepaid expenses and other current assets		220			292
Accounts payable		(1,360	)		705
Accrued expenses		(5,443	)		(2,169	)
Deferred revenue		(270	)		78

Net cash used for operating activities		(8,556	)		(2,647	)
Investing activities:
Purchases of short-term marketable securities		(5,001	)		(1,501	)
Proceeds from the sale and maturity of short-term marketable securities		4,500			4,000
Proceeds from the sale of WorldHeart common stock		—			239
Expenditures for property and equipment		(472	)		(289	)

Net cash (used in) provided by investing activities		(973	)		2,449
Financing activities:
Proceeds from the exercise of stock options		7,629			94

Net cash provided by financing activities		7,629			94
Effect of exchange rate changes on cash		220			(743	)

Net decrease in cash and cash equivalents		(1,680	)		(847	)
Cash and cash equivalents at beginning of period		5,831			4,788

Cash and cash equivalents at end of period	$	4,151		$	3,941


Supplemental disclosure:
Fixed asset additions included in accounts payable	$	44		$	31

See Accompanying Notes to Consolidated Financial Statements (Unaudited).

ABIOMED, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(In thousands, except share data)

Note 1. Nature of Business and Basis of Preparation

Abiomed, Inc. (the “Company” or “Abiomed”) is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery for acute heart failure patients. The Company’s products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and/or in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophelactically during high risk angioplasty procedures or who are in pre-shock, shock or profound cardiogenic shock.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2011 that has been filed with the Securities and Exchange Commission, or SEC.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year.

Note 2. Significant Accounting Policies

Goodwill

The Company assesses the realizability of goodwill annually, at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. These events or circumstances generally include operating losses or a significant decline in earnings associated with the acquired business or asset. The Company’s ability to realize the value of the goodwill will depend on the future cash flows of the business. If the Company is not able to realize the value of goodwill, the Company may be required to incur material charges relating to the impairment of those assets. The Company completed its annual review of goodwill as of October 31, 2010 and determined that no write-down for impairment was necessary.

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed (generally upon shipment) or services have been rendered, the selling price is fixed or determinable and collectibility is reasonably assured. Revenue from product sales to new customers is recognized when all elements of the sale have been delivered. All costs related to product shipment are recognized at time of shipment. The Company does not provide for rights of return to customers on product sales and therefore does not record a provision for returns.

Maintenance and service support contract revenues are included in product sales and are recognized ratably over the term of the service contract. Revenue is recognized as earned in limited instances in which the Company rents its console medical devices on a month-to-month basis or for a longer specified period of time to customers.

Government-sponsored research and development contracts and grants generally provide for payment on a cost-plus-fixed-fee basis. Revenues from these contracts and grants are recognized as work is performed, provided the government has appropriated sufficient funds for the work. Under contracts in which the Company spends significantly more on the development project during the term of the contract than the total contract amount, the Company prospectively recognizes revenue on such contracts ratably over the term of the contract as related research and development costs are incurred.

Share-Based Compensation

All share-based expense, including grants of employee stock options, restricted stock awards and restricted stock units, are based on the grant-date fair value of the awards, adjusted for expected forfeitures. The fair value of stock option grants is estimated using the Black-Scholes option pricing model. Use of the valuation model requires management to make certain assumptions with respect to selected model inputs. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on historical volatility of the Company’s stock. The calculation of the fair value of the options is net of estimated forfeitures. The expected term of options represents the period of time that options granted are expected to be outstanding.

Management estimates the average expected life based on historical experience of the Company’s option exercises. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historical forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model because the Company does not pay dividends and does not expect to pay any cash dividends in the foreseeable future.

The estimated fair value of all awards is recognized as compensation expense over the service period. Accruals of compensation cost for an award with a performance condition is based on the probable outcome of the performance conditions. The cumulative effects of changes in the probability outcomes are recorded in the period in which the changes occur.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies, which are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that any recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

Note 3. Fair Value Measurements

Fair value is defined as the price that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

The Company’s marketable securities were invested in the following:


	Level 1		Level 2		Level 3		Total
	(in $000’s)
At June 30, 2011:
U.S. Treasury Securities	$	54,982	$	—	$	—	$	54,982


	Level 1		Level 2		Level 3		Total
	(in $000’s)
At March 31, 2011:
U.S. Treasury securities	$	54,481	$	—	$	—	$	54,481

The Company records these marketable securities at fair value and has classified all of its investments as Level 1 since quoted market prices in active markets are readily available.

Note 4. Inventories

The components of inventories are as follows:


	June 30, 2011		March 31, 2011
	(in $000’s)
Raw materials and supplies	$	3,325	$	2,784
Work-in-progress		3,944		3,689
Finished goods		1,610		1,032

	$	8,879	$	7,505

The Company’s inventories relate to its circulatory care product lines, primarily the Impella, AB5000 and BVS 5000. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During each of the three months ended June 30, 2011 and 2010, the Company recorded $0.2 million and $0.6 million, respectively, in write downs of inventory, including excess quantities and obsolete inventory.

From time to time, the Company loans finished goods inventory on a short-term basis to customers for demonstration purposes and this inventory is generally amortized over a one to five year life. The Company had $0.7 million in demo inventory at each of June 30, 2011 and March 31, 2011, respectively. Amortization expense related to demo inventory was $0.1 million for each of the three months ended June 30, 2011 and 2010, respectively.

Note 5. Intangible Assets and Goodwill

The carrying amount of goodwill at June 30, 2011 and March 31, 2011 was $39.8 million and $38.9 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, or Impella. The goodwill activity for the three months ended June 30, 2011 is as follows:


	(in $000’s)
Balance at March 31, 2011		38,946
Exchange rate impact		806

Balance at June 30, 2011	$	39,752

The components of intangible assets are as follows:


	June 30, 2011						March 31, 2011
			Accumulated		Net Book				Accumulated		Net Book
	Cost		Amortization		Value		Cost		Amortization		Value
	(in $000’s)						(in $000’s)
Patents	$	7,239	$	6,379	$	860	$	7,099	$	6,005	$	1,094
Trademarks and tradenames		369		323		46		361		299		62
Distribution agreements		704		621		83		690		584		106
Acquired technology		2,433		2,143		290		2,384		2,014		370

	$	10,745	$	9,466	$	1,279	$	10,534	$	8,902	$	1,632

Amortization of intangible assets was $0.4 million for each of the three months ended June 30, 2011 and 2010. The Company’s expected amortization expense will be $1.0 million for the nine months ending March 31, 2012 and $0.3 million for fiscal 2013.

Note 6. Stock-Based Compensation

Total stock-based compensation recognized in the Company’s condensed consolidated statements of operations for the three months ended June 30, 2011 and 2010 was as follows:


	Three Months Ended June 30,
	2011		2010
	(in $000’s)
Cost of product revenue	$	76	$	62
Research and development		500		310
Selling, general and administrative		1,756		999

	$	2,332	$	1,371

The $2.3 million in stock-based compensation expense for the three months ended June 30, 2011 includes $0.9 million related to stock options and $1.4 million related to restricted stock, restricted stock units and the Company’s Employee Stock Purchase Plan, or ESPP. Stock compensation related to restricted stock and restricted stock units is primarily related to performance share awards, as described in more detail below. The $1.4 million in stock-based compensation expense for the three months ended June 30, 2010 includes $1.0 million related to stock options and $0.4 million related to restricted stock and the Company’s ESPP.

The remaining unrecognized stock-based compensation expense for unvested stock option awards at June 30, 2011 was approximately $5.6 million, net of forfeitures, and the weighted-average time over which this cost will be recognized is 2.4 years.

Stock Option Activity

The following table summarizes the stock option activity for the three months ended June 30, 2011:


						Weighted
				Weighted		Average		Aggregate
				Average		Remaining		Intrinsic
	Options			Exercise		Contractual		Value
	(in thousands)			Price		Term (years)		(in thousands)
Outstanding at April 1, 2011		5,945		$	10.27		6.30
Granted		39			16.83
Exercised		(799	)		9.51
Cancelled		(109	)		11.59
Expired		(52	)		23.51

Outstanding at June 30, 2011		5,024		$	11.85		6.46	$	31,443

Exercisable at June 30, 2011		3,565		$	10.64		5.67	$	20,140

The total intrinsic value of options exercised was $5.8 million for the three months ended June 30, 2011. The total fair value of options vested during the three months ended June 30, 2011 was $10.0 million.

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The fair value of options granted during the three months ended June 30, 2011 were calculated using the following weighted-average assumptions:


		Three Months Ended June 30,
		2011
Risk-free interest rate		1.83%
Expected option life (years)		5.30
Expected volatility		51.6%

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock. The Company estimates the expected term based on historical experience. The expected dividend yield was zero, since the Company does not pay cash dividends and does not expect to pay cash dividends in the future. The calculation of the fair value of the options is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historic forfeitures may not be indicative of forfeitures in the future.

The weighted-average grant-date fair value for options granted during the three months ended June 30, 2011 was $8.39.

Restricted Stock and Restricted Stock Units

In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity as follows:


	Three Months Ended
	June 30, 2011
	Number of Shares (in 000’s)			Weighted Average Grant Date Fair Value
Restricted stock awards and restricted stock units at April 1, 2011		407		$	9.84
Granted		564			18.49
Vested		(134	)		10.88
Forfeited		—			—

Restricted stock awards and restricted stock units at June 30, 2011		837		$	15.51

The remaining unrecognized compensation expense for restricted stock awards and restricted stock units, including performance based awards, at June 30, 2011 was approximately $10.1 million and the weighted-average time over which this cost will be recognized is 2.7 years.

Performance Based Awards

Included in the restricted stock activity discussed above are certain awards granted in fiscal 2011 and 2012 that contain performance based vesting.

During the three months ended June 30, 2010, 311,000 shares of restricted stock and a performance award for the potential issuance of 45,000 shares of common stock were issued to certain executive officers and members of senior management of the Company, all of which could vest upon achievement of prescribed performance milestones. During the year ended March 31, 2011, the Company determined that it met the prescribed performance targets.

During the three months ended June 30, 2011, the Company determined that it should have been using the graded vesting method instead of the straight-line method to expense stock-based compensation for the performance based awards issued in June 2010. This resulted in additional stock based compensation expense of approximately $0.6 million being recorded during the three months ended June 30, 2011 that should have been recorded during the year ended March 31, 2011. The Company believes that the amount is not material to its March 31, 2011 consolidated financial statements and has therefore recorded the adjustment in the current quarter.

During the three months ended June 30, 2011, performance awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management, all of which could vest upon achievement of prescribed revenue performance milestones. As of June 30, 2011, the Company believes it is probable that it will meet the prescribed performance targets for these awards.

As of June 30, 2011, the Company has recorded $2.2 million in stock-based compensation for shares and options in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these shares and options at June 30, 2011 is $5.8 million based on the Company’s current assessment of probability of achieving the performance milestones.

Note 7. Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to tax benefit carryforwards and to differences between the financial statement amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates. A valuation reserve is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The tax benefit associated with the stock option compensation deductions will be credited to equity when realized.

As of June 30, 2011, the Company has accumulated a net deferred tax liability in the amount of $4.1 million which is the result of a difference in accounting for the Company’s goodwill which is amortized over 15 years for tax purposes, but not amortized for book purposes. The net deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period.

The Company and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All open tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. However, since the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carry forwards are utilized.

Note 8. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported basic and dilutive loss per share is the same value.

Excluded from the calculation of diluted weighted-average shares outstanding are underlying outstanding stock options of approximately 5,024,000 shares and 6,058,000 shares as of June 30, 2011 and 2010, respectively, and unvested shares of restricted stock and restricted stock units of approximately 837,000 shares and 653,000 shares as of June 30, 2011 and 2010, respectively.

Note 9. Commitments and Contingencies

Litigation

From time to time, the Company is involved in legal and administrative proceedings and claims of various types. While any litigation contains an element of uncertainty, management presently believes that the outcome of each such proceedings or claims which are pending or known to be threatened, or all of them combined, is not expected to have a material effect on the Company’s financial position, and results of operations or cash flows. At June 30, 2011, the Company did not have any material pending litigation.

Note 10. Accrued Expenses

Accrued expenses consist of the following:


	June 30, 2011		March 31, 2011
	(in $000’s)
Salaries and benefits	$	5,177	$	7,416
Research and development		1,216		3,991
Professional, accounting and audit fees		463		616
Warranty		599		537
Other		1,245		1,518

	$	8,700	$	14,078

Note 11. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief

Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 61% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2011 and March 31, 2011, respectively. Remaining assets are located in Europe, primarily related to the Company’s Impella production facility, and include goodwill and intangibles of $41.0 million and $40.5 million at June 30, 2011 and March 31, 2011, respectively. Total assets in Europe excluding goodwill and intangibles amounted to 8%, respectively, of total consolidated assets at each of June 30, 2011 and March 31, 2011. For each of the three months ended June 30, 2011 and 2010, international sales accounted for 7% of total product revenue.

ITEM 2:

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

Abiomed’s discussion of financial condition and results of operations may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, market acceptance of our new products, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks detailed in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Report. In particular, we encourage you to review the risks and uncertainties discussed under Item 1A of Part I of our Annual Report on Form 10-K, for the year ended March 31, 2011. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Report or to reflect the occurrence of unanticipated events.

OVERVIEW

We are a leading provider of medical devices in circulatory support and we offer a continuum of care in heart recovery for acute heart failure patients. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Our products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and/or in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically during high risk angioplasty procedures or who are in pre- shock, shock or profound cardiogenic shock. We believe heart recovery is the optimal clinical outcome by restoring the quality of life of patients. In addition, we believe heart recovery is the most cost-effective path for the healthcare system.

Our strategic focus and the driver of the most recent revenue growth in our business is the market penetration of our Impella 2.5 product, which received 510(k) clearance in June 2008 for partial circulatory support for up to six hours. In December 2010, we announced the termination of the Protect II study based on a futility determination at the planned interim analysis regarding the primary end-point, which we view as likely to have resulted from how rotational athorectomy was used in the study. In April 2011, we announced the final results from the Protect II study, including those patients enrolled following the initiation of the interim analysis, which showed a statistically significant 21% reduction in major adverse events compared to the intra aortic balloon at 90 days per protocol. We received 510(k) clearance in April 2009 for our Impella 5.0 and Impella LD devices for circulatory support for up to 6 hours. These devices are larger and provide more blood flow than the Impella 2.5.

Revenues from our other heart recovery products, largely focused on the heart surgery suite, have been lower recently as we have strategically shifted our sales and marketing efforts towards our Impella products and the cath lab. We have from time to time engaged in console placement programs related to our iPulse consoles, in order to encourage utilization of our BVS and AB5000 disposables. We have also developed a portable driver for our AB5000 product which received FDA approval under a post-marketing application, or PMA, supplement in March 2009. This clearance allows the AB5000 portable driver to be used in U.S. hospitals for in hospital and transport use. Our BVS product was launched in 1992 and revenue from this product has been declining as AB5000, our next-generation product for heart recovery, is designed to provide a longer duration of support than the BVS 5000 and, when used with the portable driver, facilitates patient mobility in the hospital. We expect revenue from BVS to continue to decline as our customers transition to AB5000 disposables and the Impella 5.0 and LD products geared for the surgery suite. We expect revenues from our non-Impella business during fiscal 2012 will continue to decrease as we continue to focus on our Impella products. In addition, we do not expect that revenues from sales of our replacement heart product, the AbioCor, will be a material portion of our total revenues for the foreseeable future as our primary strategic focus is centered on heart recovery for acute heart failure patients. We have incurred net losses since our inception, including a net loss of $4.6 million for the three months ended June 30, 2011. We expect to incur additional net losses in the future as we continue to expand our commercial infrastructure and invest in clinical trials and research and development expenses related to our products.

Impella 2.5

The Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors. The device is designed primarily for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 2.5 device received 510(k) clearance from the U.S. Food and Drug Administration, or FDA, in June 2008 for partial circulatory support for up to six hours, has CE mark approval in Europe for up to five days of use and is approved for use in over 40 countries.

The Impella 2.5 catheter can be quickly inserted via the femoral artery to reach the left ventricle of the heart where it is directly deployed to draw blood out of the ventricle, deliver it to the arterial system and perfuse the heart muscle. This function is intended to reduce ventricular work (resting the heart) and provide flow to vital organs. The Impella 2.5 is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute.

In August 2007, we received approval from the FDA to begin a high-risk percutaneous coronary intervention, or PCI, pivotal clinical trial, known as the Protect II study, for the Impella 2.5. This pivotal study was to determine the safety and effectiveness of the Impella 2.5 as compared to optimal medical management with an intra-aortic balloon, or IAB, during “high-risk” angioplasty procedures. In December 2010, we announced the termination of the Protect II study based on a futility determination at the planned interim analysis regarding the primary end-point, which we view as likely to have resulted from how rotational athorectomy was used in the study. In April 2011, we announced final results from the Protect II study, including those patients enrolled following the initiation of the interim analysis, which showed a statistically significant 21% reduction in major adverse events compared to the IAB at 90 days per protocol.

In addition to the FDA approved studies for Impella 2.5, we are also conducting USpella, the first U.S. multicenter observational registry collecting clinical data and outcomes for patients supported with Impella 2.5 during elective, urgent and emergent procedures. We invited 62 hospitals in the U.S. and Canada to participate in the USpella registry.

Impella 5.0 and Impella LD

The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella 5.0 and Impella LD devices received 510(k) clearance in April 2009, for circulatory support for up to six hours and have CE mark approval in Europe and are approved for use in over 40 countries.

The Impella 5.0 is implanted via a small incision in the femoral artery in the groin and can be quickly inserted via the femoral artery using a guide wire to reach the left ventricle of the heart where it is directly deployed to draw blood out of the ventricle, deliver it to the arterial system and perfuse the heart muscle. This function is intended to reduce ventricular work (resting the heart). The Impella LD is similar to the Impella 5.0 but is implanted directly through an incision in the subclavian vein or through an aortic graft. The Impella 5.0 and Impella LD can pump up to five liters of blood per minute and have been used to treat patients in need of cardiac support resulting from post-cardiotomy cardiogenic shock, myocarditis, low cardiac output after a heart attack, or post-coronary intervention procedures.

AB5000 and BVS 5000

We manufacture and sell the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. We believe the AB5000 and BVS 5000 systems are the only commercially available cardiac assist devices that are approved by the FDA for all indications where heart recovery is the intended outcome, including patients who have undergone successful cardiac surgery and subsequently develop low cardiac output, or patients who suffer from acute cardiac disorders leading to hemodynamic instability.

We have developed a Portable Circulatory Support Driver for both in-hospital and out-of-hospital patients. The Portable Driver is designed to support our AB5000 VAD. We received CE mark approval for our Portable Driver in March 2008. In May 2008, we received conditional approval for the Portable Driver under an IDE to conduct a U.S. patient discharge study at 20 hospitals for 30 patients. In March 2009, we received FDA approval of our PMA supplement for the AB Portable™ Driver. This clearance allows for commercial shipment of the device to U.S. hospitals for in hospital and transport use. Out-of-hospital use is being studied in the U.S. in a U.S. clinical trial, which, when successfully completed, would allow patients to go home while waiting for recovery.

AbioCor

Our AbioCor Implantable Replacement Heart is the first completely self-contained artificial heart. Designed to sustain the body’s circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Patients with advanced age, impaired organ function or cancer are generally ineligible for a heart transplant and are potential candidates to receive the AbioCor implantable heart. Once implanted, the AbioCor system does not penetrate the skin, reducing the chance of infection. This technology provides patients with mobility and remote diagnostics. The use of AbioCor is limited to normal to larger sized male patients and has a product life expectancy of 18-24 months.

We received a Humanitarian Device Exemption, or HDE, supplement approval from the FDA for product enhancement of the AbioCor in January 2008. HDE approval signifies that no comparable alternative therapy exists for patients facing imminent death without the technology. HDE approval allows the AbioCor to be made available to a limited patient population, with no more than 4,000 patients receiving the technology in the U.S. each year under HDE approval limits. Because the AbioCor is only available to a limited patient population, we do not expect that demand will meet the 4,000 patient limit under HDE approval. We have no current plans to seek a broader regulatory approval of the AbioCor. We do not expect that revenues from sales of the AbioCor will be a material portion of our total revenues for the foreseeable future as our primary strategic focus is centered on heart recovery for acute heart failure patients.

Critical Accounting Policies

Goodwill and Intangible Assets

We evaluate goodwill for impairment at least annually using forecasts of discounted future cash flows. Estimates of future cash flows require assumptions related to revenue and operating income growth, asset-related expenditures, working capital levels and other factors. Different assumptions from those made in our analysis could materially affect projected cash flows and our evaluation of goodwill for impairment. Should the fair value of goodwill decline because of reduced operating performance, market declines, delays in regulatory approval, other indicators of impairment, or as a result of changes in the discount rate, charges for impairment of goodwill may be necessary. We performed our annual impairment review for fiscal 2011 as of October 31, 2010 and determined that no write-down for impairment of goodwill was required as the fair value of the reporting unit substantially exceeded the carrying value.

We estimate the fair value of acquisition-related intangible assets principally based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. We review intangible assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Factors considered important which could trigger an impairment review include significant changes relative to: (i) projected future operating results; (ii) the use of the assets or the strategy for the overall business; (iii) business collaborations; and (iv) industry, business, or economic trends and developments. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If it is determined that the carrying value of intangible assets may not be recoverable, the asset is written down to its estimated fair value on a discounted cash flow basis.

Revenue Recognition

We recognize revenue when evidence of an arrangement exists, title has passed (generally upon shipment) or services have been rendered, the selling price is fixed or determinable and collectibility is reasonably assured. Revenue from product sales to new customers is deferred until all elements of the sale have been delivered. All costs related to product shipment are recognized at time of shipment. We do not provide for rights of return to customers on our product sales and therefore do not record a provision for returns.

Maintenance and service support contract revenues are included in product revenue and are recognized ratably over the term of the service contracts. In limited instances, we rent console medical devices on a month-to-month basis or for a longer specified period of time to customers for which revenue is recognized as earned.

Government-sponsored research and development contracts and grants generally provide for payment on a cost-plus-fixed-fee basis. Revenues from these contracts and grants are recognized as work is performed. Under contracts in which we elect to spend significantly more on the development project during the term of the contract than the total contract amount, we prospectively recognize revenue on such contracts ratably over the term of the contract as related research and development costs are incurred.

Share-Based Compensation

All share-based expense is estimated using the Black-Scholes option pricing model. Use of a valuation model requires us to make certain assumptions with respect to selected model inputs. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on historical volatility of our stock. The calculation of the fair value of the options is net of estimated forfeitures. The expected term of options represents the period of time that options granted are expected to be

outstanding. We estimate the average expected life based on historical experience of our option exercises. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historical forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model because we do not pay cash dividends and do not expect to pay any cash dividends in the foreseeable future.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies, which are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

Results of Operations

The following table sets forth certain consolidated statements of operations data for the periods indicated as a percentage of total revenues (which includes revenues from products and funded research and development) for the three months ended June 30, 2011 and 2010, respectively:


	Three Months Ended June 30,
	2011			2010
Revenues:
Products		99.3	%		98.9	%
Funded research and development		0.7			1.1

		100.0			100.0


Costs and expenses:
Cost of product revenue excluding amortization of intangibles		21.5			24.0
Research and development		26.8			30.2
Selling, general and administrative		66.4			71.6
Amortization of intangible assets		1.4			1.7

		116.1			127.5

Loss from operations		(16.1	)		(27.5	)

Other (expense) income :
Investment income (expense), net		—			(0.1	)
Gain on sale of WorldHeart stock		—			1.1
Other (expense) income, net		(0.3	)		0.4

		(0.3	)		1.4

Loss before provision for income taxes		(16.4	)		(26.1	)
Provision for income taxes		0.4			1.1

Net loss		(16.8	)%		(27.2	)%

Three months ended June 30, 2011 compared with the three months ended June 30, 2010

Revenues

Our revenues are comprised of the following:


	Three Months Ended June 30,
	2011		2010
	(in $000's)
Impella products	$	22,192	$	16,745
Other products		3,424		3,879
Service		1,550		1,137

Total product and service revenues	$	27,166	$	21,761
Funded research and development		189		241

Total revenues	$	27,355	$	22,002

Impella revenue encompasses Impella 2.5, Impella 5.0, and Impella LD product sales. Other revenue includes AB5000, BVS5000 and cannulae product sales. Service revenue represents revenue earned on service contracts and maintenance calls.

Total revenues for the three months ended June 30, 2011 increased by $5.4 million, or 25%, to $27.4 million from $22.0 million for the three months ended June 30, 2010. The increase in total revenue was primarily due to higher Impella orders due to greater demand in the U.S.

Impella revenues for the three months ended June 30, 2011 increased by $5.5 million, or 33% to $22.2 million from $16.7 million for the three months ended June 30, 2010. Most of our Impella revenue was from disposable product sales of Impella in the U.S., as we focus on increasing utilization of these products through continued sales force and physician training.

Other product revenues for the three months ended June 30, 2011 decreased by $0.5 million, or 13%, to $3.4 million from $3.9 million for the three months ended June 30, 2010. The decrease in other revenue was due to a decline in BVS and AB5000 disposable revenue as well as a decrease in console revenue supporting these product lines. We expect that BVS and AB5000 revenue will continue to decline in fiscal 2012 as we focus our sales efforts in the surgical suite on Impella 5.0 and LD.

Service revenue for the three months ended June 30, 2011 increased by $0.5 million, or 45%, to $1.6 million from $1.1 million for the three months ended June 30, 2010. The increase in service revenue was primarily due to an increase in service contracts in support of maintenance of consoles at customers.

Cost of Product Revenues

Cost of product revenues for the three months ended June 30, 2011 and 2010, respectively, was $5.9 million and $5.3 million. Gross margin was 78.5% for the three months ended June 30, 2011 compared to 76.0% for the three months ended June 30, 2010. The increase in gross margin was primarily due to a larger portion of revenues from disposable products, improved manufacturing production and lower writedowns on inventory.

Research and Development Expenses

Research and development expenses for the three months ended June 30, 2011 increased by $0.6 million, or 9%, to $7.3 million from $6.7 million for the three months ended June 30, 2010, primarily due to increased project spending on new product development. Research and development expenses for the three months ended June 30, 2011 and 2010 included $2.5 million in each quarter , in clinical trial expenses primarily associated with our Impella 2.5 U.S. trials.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended June 30, 2011 increased by $2.4 million, or 15%, to $18.2 million from $15.8 million for the three months ended June 30, 2010. The increase in selling, general and administrative expenses was due to increased field headcount as we concentrate our marketing focus on commercial efforts in the U.S. and an increase in stock-based compensation expense due in part to changes made in assumptions during the quarter regarding how expense is recognized over the service period for performance-based awards.

We expect to increase our expenditures on sales and marketing activities in fiscal 2012, with particular investments in clinical personnel with cath lab expertise. We also plan to increase our marketing, service, and training investments to support the efforts of the sales and field clinical teams to drive recovery awareness for acute heart failure patients.

Amortization of Intangibles

Amortization of intangible assets was $0.4 million for each of the three months ended June 30, 2011 and 2010. Amortization expense primarily is related specifically to intangible assets acquired in the Impella acquisition.

Gain on Sale of WorldHeart Stock

During the three months ended June 30, 2010, we sold 100,000 shares of WorldHeart common stock, which resulted in a gain of $0.2 million. At June 30, 2011, we have no remaining shares of WorldHeart common stock.

Provision for Income Taxes

We recorded an income tax provision of $0.1 million and $0.2 million for the three months ended June 30, 2011 and 2010, respectively. The income tax provision is due to deferred tax related to our goodwill, which is amortizable over 15 years for tax purposes but not amortized for book purposes. The net deferred tax liability cannot be offset against our deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period.

Net Loss

During the three months ended June 30, 2011, we incurred a net loss of $4.6 million, or $0.12 per share, compared to a net loss of $6.0 million, or $0.16 per share, for the three months ended June 30, 2010. The decrease in the net loss was due to increased Impella sales due to greater demand in the U.S.

Liquidity and Capital Resources

At June 30, 2011, our cash, cash equivalents, and short-term marketable securities totaled $59.1 million, a decrease of $1.2 million compared to $60.3 million at March 31, 2011. We believe that our revenue from product sales together with existing resources will be sufficient to fund our operations for at least the next twelve months, exclusive of activities involving any future acquisitions of products or companies that complement or augment our existing line of products.

Marketable securities at June 30, 2011 consist of $55.0 million held in funds that invest solely in U.S. Treasury securities. We are not a party to any interest rate swaps, currency hedges or derivative contracts of any type and have no exposure to commercial paper or auction rate securities markets. We continue to monitor our cash position closely and currently only invest excess cash in short term U.S. treasury securities.

We will continue to closely monitor our liquidity and the overall health of the credit markets. However, we cannot predict with any certainty the impact on us of any further disruption in the credit environment. Our primary liquidity needs are to fund the expansion of our commercial infrastructure in the U.S., increase our Impella manufacturing capacity, fund new product development and provide for general working capital needs. Through June 30, 2011, we have funded our operations principally from product sales and through the sale of equity securities, including our August 2008 stock offering in which we received proceeds of $42.0 million. We also generate cash through funded research and development revenue.

Our operating activities during the three months ended June 30, 2011 used cash of $8.6 million as compared to $2.6 million during the same period in the prior year. Our net loss for the three months ended June 30, 2011 of $4.6 million contributed to our cash used for operations. Also contributing to our cash used for operations was a $1.6 million increase in inventory, a $0.3 million decrease in deferred revenue, and a $6.8 million decrease in accounts payable and accrued expenses primarily due to the payment of annual employee bonuses in the first quarter and payments related to the closeout of the Protect II study. These decreases in cash were partially offset by a $0.8 million increase in accounts receivable due to higher customer billings as well as non-cash adjustments of $2.3 million related to stock-based compensation expense and $1.0 million of depreciation and amortization.

Our investing activities during the three months ended June 30, 2011 used cash of $1.0 million as compared to a generation of cash of $2.4 million during the same period in the prior year. Cash used by investment activities for the three months ended June 30, 2011 consisted primarily of $0.5 million of purchases of short-term marketable securities, net of proceeds, during the period. We also incurred $0.5 million of cash expenditures for property and equipment primarily for the purchase of manufacturing equipment and computer software.

Our financing activities during each of the three months ended June 30, 2011 and 2010 provided cash of $7.6 million and $0.1 million, respectively. Cash provided by financing activities during the three months ended June 30, 2011 were attributable to the exercise of stock options.

Capital expenditures for fiscal 2012 are estimated to be $2.5 to $4.0 million, which relate primarily to our planned manufacturing capacity increases for Impella and software development projects.

Our liquidity is influenced by our ability to sell our products in a competitive industry and our customers’ ability to pay for our products. Factors that may affect liquidity include our ability to penetrate the market for our products, maintain or reduce the length of the selling cycle, and collect cash from clients after our products are sold. We continue to review our long-term cash needs on a regular basis. We have no debt outstanding.

ITEM 3:

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Primary Market Risk Exposures

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio. Our cash and marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. If market interest rates were to increase immediately and uniformly by 10 percent from levels at June 30, 2011, we believe the decline in fair market value of our investment portfolio would be immaterial. Marketable securities at June 30, 2011 consist of $55.0 million in five funds that invest in U.S. Treasury securities and related interest.

Currency Exchange Rates

Our foreign subsidiaries’ primary functional currency is the Euro. Therefore, our investment in our foreign subsidiaries is sensitive to fluctuations in currency exchange rates. The effect of a change in currency exchange rates on our net investment in international subsidiaries is reflected in the accumulated other comprehensive income component of stockholders’ equity. Had a 10% depreciation in foreign currencies occurred relative to the U.S. dollar as of June 30, 2011, the result would have been a reduction of stockholders’ equity of approximately $4.2 million.

Fair Value of Financial Instruments

At June 30, 2011, our financial instruments consist primarily of cash and cash equivalents, short-term marketable securities, accounts receivable, and accounts payable. The estimated fair values of the financial instruments have been determined by us using available market information and appropriate valuation techniques. Considerable judgment is required, however, to interpret market data to develop the estimates of fair value. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of June 30, 2011. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2011, these disclosure controls and procedures are effective to provide reasonable assurance that material information required to be disclosed by us, including our consolidated subsidiaries, in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Evaluation of Changes in Internal Control over Financial Reporting

During the first quarter of our fiscal year ended March 31, 2012, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.

Legal Proceedings

We are from time to time involved in various legal actions, the outcomes of which are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. We record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. We review these estimates each accounting period as additional information is known and adjust the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements.

Item 1A.

Risk Factors

Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part 1, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2011, which could materially affect our business, financial condition or future results. To the best of our knowledge, as of the date of this report, the only material change to the risk factors described in our Annual Report on Form 10-K is to replace the similarly titled risk factor in the annual report with the risk factor set forth below.

If the FDA or another regulatory agency determines that we have promoted off-label use of our products, we may be subject to various penalties, including civil or criminal penalties.

The FDA and other regulatory agencies actively enforce regulations prohibiting promotion of off-label uses and the promotion of products for which marketing clearance has not been obtained. If the FDA or another regulatory agency determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and criminal penalties. Although our policy is to refrain from statements that could be considered off-label promotion of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. In June 2011, we received a warning letter from the FDA stating that some of our promotional materials marketed the Impella 2.5 for uses that had not been approved by the FDA. We have cooperated with the FDA in addressing its concerns and believe that we have resolved the matter without any penalties. Although we believe that this issue has been resolved, if similar matters come up in the future, we may not be able to resolve them without facing significant consequences. Such matters could result in reduced demand for our products and would have a material adverse effect on our operations and prospects.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults Upon Senior Securities

None

Item 4.

(Removed and Reserved)

Item 5.

Other Information

None

Item 6.

Exhibits

Exhibit
No.

Description

Filed with

This

Form 10-Q

Incorporated by Reference

Form

Filing Date

Exhibit
No.

3.1

Restated Certificate of Incorporation.

S-3

September 29, 1997

3.1

3.2

Restated By-Laws, as amended.

10-K

May 27, 2004

3.2

3.3

Certificate of Designations of Series A Junior Participating Preferred Stock.

S-3

September 29, 1997

3.3

3.4

Amendment to the Company’s Restated Certificate of Incorporation to increase the authorized shares of common stock from 25,000,000 to 100,000,000.

8-K

March 21, 2007

3.4

4.1

Specimen Certificate of common stock.

S-1

June 5, 1987

4.1

10.1

Form of Performance Share Award Agreement (Performance and Time Based RSU).*

10.2

Form of Performance Share Award Agreement (Time Based RSU).*

11.1

Statement regarding computation of Per Share Earnings (see Note 11, Notes to Consolidated Financial Statements).

31.1

Rule 13a-14(a)/15d-14(a) certification of principal executive officer.

31.2

Rule 13a-14(a)/15d-14(a) certification of principal accounting officer.

32.1

Section 1350 certification.

101

The following financial information from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets as of June 30, 2011 and March 31, 2011; (ii) Consolidated Statements of Operations for the three months ended June 30, 2011 and June 30, 2010; (iii) Consolidated Statements of Cash Flows for the three months ended June 30, 2011 and June 30, 2010; and (iv) Notes to Consolidated Financial Statements.**

*	Management contract or compensatory plan.

The information contained in this exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

ABIOMED, INC. AND SUBSIDIARIES

PART II. OTHER INFORMATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		Abiomed, Inc.

Date: August 5, 2011		/S/ ROBERT L. BOWEN
		Robert L. Bowen
		Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-10.1 2 dex101.htm FORM OF PERFORMANCE SHARE AWARD (PERFORMANCE AND TIME BASED RSU) Form of Performance Share Award (Performance and Time Based RSU)

Exhibit 10.1

ABIOMED, Inc.

Performance Share Award Agreement

(Performance and Time Based RSUs)

This Performance Share Award Agreement (this “Agreement”) is made effective as of (the “Grant Date”), between ABIOMED, Inc. (the “Company”), and (the “Employee”), pursuant to the Company’s 2008 Stock Incentive Plan, as it may be amended from time to time (the “Plan”). This Agreement is expressly subject to all of the terms and conditions contained in the Plan, which is hereby incorporated herein by reference. In the event that any of the terms and conditions contained in this Agreement are inconsistent with the Plan, the terms of the Plan shall control. All capitalized terms not defined in this Agreement have the meanings specified in the Plan.

WITNESSETH:

1. Performance and Time Based Restricted Stock Units. The maximum number of shares of common stock of the Company (“Stock”) eligible for issuance under this Agreement shall be shares of Stock (the “Maximum Shares”). The Stock shall only be issuable to the extent that the below criteria are met so that they become Performance Shares, and then only to the extent that the Employee meets the time-based vesting conditions set forth below. The Maximum Shares shall become “Performance Shares” as follows: [Describe performance based vesting conditions.]

On each of the following dates (each, a “Vesting Date”), and provided that the Employee is employed by the Company on such Vesting Date, the Employee shall be entitled to receive a grant of Stock as set forth below: [Describe time based vesting conditions.]

Certificates for the Stock issued as set forth above shall be issued as soon as practicable following each Vesting Date, but in no event later than thirty days following each Vesting Date

2. Termination of Employment. The Employee understands and agrees that if the Employee ceases to be an employee of the Company or a subsidiary of the Company at any time for any reason, whether because of any action of the Company or the Employee, the death or incapacity of the Employee or otherwise (the date of such termination of employment, the “Termination Date”), the Employee’s only rights under this Agreement shall be the right to receive Stock, if any, that was to be issued (but was not yet issued) pursuant to a Vesting Date that was reached prior to the Termination Date, and the Employee shall have no right to the issuance of Stock with respect to any Vesting Date that is reached after the Termination Date.

3. Lock-Up Agreement. The Employee agrees that upon the request of the Company or the managing underwriter(s) of any offering of securities of the Company that is the subject of a registration statement filed under the Securities Act of 1933, as amended, for a period of time (not to exceed 180 days, plus such additional number of days (not to exceed 35) as may reasonably be requested to enable the underwriter(s) of such offering to comply with Rule 2711(f) of the Financial Industry Regulatory Authority or any amendment or successor thereto) from the effective date of the registration statement under the Act for such offering, the Employee will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Stock issued pursuant to this Agreement, without the prior written consent of the Company and such underwriters.

4. Discretion of the Committee. Unless otherwise provided, the Committee shall make all determinations required to be made hereunder, including determinations required to be made by the Company, which shall include determinations of Fiscal 2012 Revenue and the calculation of the number of Performance Shares hereunder, and shall interpret all provisions of this Agreement, as it deems necessary or desirable, in its sole and unfettered discretion. Such determinations and interpretations shall be binding and conclusive as to the Company and the Employee. If there shall be no Compensation Committee of the Corporation’s Board of Directors or if the Board of Directors shall determine that the Board of Directors shall administer this Agreement, all references herein to the Committee shall be deemed references to the Board of Directors.

5. Withholding Taxes. The Employee acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Employee any federal, state or local taxes of any kind required by law to be withheld with respect to the issuance of Stock pursuant to Section 1 above, and understands that the Company may refuse to issue any Stock pursuant to this Agreement unless arrangements satisfactory to the Company have been reached with respect to the payment of such taxes.

6. No Rights to Employment. Nothing contained in this Agreement shall be construed as giving the Employee any right to continued employment with the Company, or to establish or maintain an on-going business relationship with the Company. The Employee acknowledges and agrees that the transactions contemplated hereunder do not constitute an express or implied promise of continued employment for any period, or at all.

- 2 -

7. No Rights as a Shareholder. The Employee shall have no rights as a shareholder of the Company as a result of this Agreement unless and until shares of Stock have been issued to the Employee pursuant to Section 1 above.

8. Notices. Any notices required to be given under this Agreement shall be sufficient if in writing and if sent by certified mail, return receipt requested, and addressed as follows:

if to the Corporation:

ABIOMED, Inc.

22 Cherry Hill Drive

Danvers, Massachusetts 01923

Attn: Chief Financial Officer

if to the Employee, at the address of the Employee set forth in the Company’s records or to such other address as either party may designate under the provisions hereof.

9. Applicable Law. All rights and obligations under this Agreement shall be governed by the laws of The Commonwealth of Massachusetts, without regard to its conflicts of law principles.

IN WITNESS WHEREOF, the parties have executed this Agreement as an instrument under seal effective as of the date written on the first page of this Agreement.

ABIOMED, Inc.

By: Michael R. Minogue

Its: President and Chief Executive Officer

EMPLOYEE:

Print name:

Acceptance date:

- 3 -

EX-10.2 3 dex102.htm FORM OF PERFORMANCE SHARE AWARD (TIME BASED RSU) Form of Performance Share Award (Time Based RSU)

Exhibit 10.2

ABIOMED, Inc.

Performance Share Award Agreement

(Time Based RSUs)

WITNESSETH:

1. Time Based Restricted Stock Units. On each of the following dates (each, a “Vesting Date”), and provided that the Employee is employed by the Company on such Vesting Date, the Employee shall be entitled to receive a grant of Stock as set forth below: [Describe time based vesting conditions.]

Certificates for the Stock issued as set forth above shall be issued as soon as practicable following each Vesting Date, but in no event later than thirty days following each Vesting Date

2711(f) of the Financial Industry Regulatory Authority or any amendment or successor thereto) from the effective date of the registration statement under the Act for such offering, the Employee will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Stock issued pursuant to this Agreement, without the prior written consent of the Company and such underwriters.

4. Discretion of the Committee. Unless otherwise provided, the Committee shall make all determinations required to be made hereunder, including determinations required to be made by the Company, and shall interpret all provisions of this Agreement, as it deems necessary or desirable, in its sole and unfettered discretion. Such determinations and interpretations shall be binding and conclusive as to the Company and the Employee. If there shall be no Compensation Committee of the Corporation’s Board of Directors or if the Board of Directors shall determine that the Board of Directors shall administer this Agreement, all references herein to the Committee shall be deemed references to the Board of Directors.

8. Notices. Any notices required to be given under this Agreement shall be sufficient if in writing and if sent by certified mail, return receipt requested, and addressed as follows:

if to the Corporation:

ABIOMED, Inc.

22 Cherry Hill Drive

Danvers, Massachusetts 01923

Attn: Chief Financial Officer

if to the Employee, at the address of the Employee set forth in the Company’s records or to such other address as either party may designate under the provisions hereof.

- 2 -

9. Applicable Law. All rights and obligations under this Agreement shall be governed by the laws of The Commonwealth of Massachusetts, without regard to its conflicts of law principles.

IN WITNESS WHEREOF, the parties have executed this Agreement as an instrument under seal effective as of the date written on the first page of this Agreement.

ABIOMED, Inc.

By: Michael R. Minogue

Its: President and Chief Executive Officer

EMPLOYEE:

Print name:

Acceptance date:

- 3 -

EX-31.1 4 dex311.htm CERTIFICATION OF THE PRESIDENT AND CEO PURSUANT TO SECTION 302 Certification of the President and CEO Pursuant to Section 302

Exhibit 31.1

CERTIFICATIONS

I, Michael R. Minogue certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ABIOMED, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 5, 2011		/s/ Michael R. Minogue
		Michael R. Minogue
		Chairman, President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 5 dex312.htm CERTIFICATION OF THE VICE PRESIDENT AND CFO PURSUANT TO SECTION 302 Certification of the Vice President and CFO Pursuant to Section 302

Exhibit 31.2

I, Robert L. Bowen certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ABIOMED, Inc.

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 5, 2011		/s/ Robert L. Bowen
		Robert L. Bowen
		Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-32.1 6 dex321.htm CERTIFICATION OF THE PRESIDENT & CEO AND VP & CFO PURSUANT TO SECTION 906 Certification of the President & CEO and VP & CFO Pursuant to Section 906

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ABIOMED, Inc., (the “Company”) for the quarter ended June 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned President and Chief Executive Officer, and Corporate Controller, of the Company, certifies, to the best knowledge and belief of the signatory, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Michael R. Minogue				/s/ Robert L. Bowen
Chairman, President and Chief Executive Officer				Vice President and Chief Financial Officer
Date: August 5, 2011				Date: August 5, 2011

EX-101.INS 7 abmd-20110630.xml XBRL INSTANCE DOCUMENT 38523668

3941000

1772000

827000

15379000

1715000

-279364000

8700000

1339000

14541000

131137000

385000

8879000

38509793

1000000

83892000

39752000

469000

4151000

0.01

389217000

54982000

4106000

131137000

111183000

38560747

0.01

6214000

100000000

19954000

50954

4964000

1279000

4788000

745000

827000

22343000

1982000

-274770000

14078000

1544000

15376000

131588000

377000

7505000

37705765

1000000

84737000

38946000

492000

5831000

0.01

379218000

54481000

4010000

131588000

104743000

37756719

0.01

6273000

100000000

26845000

50954

6283000

1632000

94000

2449000

81000

-767000

5284000

22002000

28057000

-2647000

-5737000

1371000

1501000

-5000

-2169000

243000

53000

-5980000

318000

6653000

239000

4000000

623000

289000

959000

367000

-6055000

705000

21761000

241000

15753000

243000

-847000

-292000

-743000

31000

-645000

-2000

78000

94000

-0.16

239000 37086000 Q1 ABMD ABIOMED INC false Accelerated Filer 2011 10-Q 2011-06-30 0000815094 --03-31

7629000

-973000

-81000

-847000

5891000

27355000

<div> Note 9. Commitments and Contingencies  Litigation From time to time, the Company is involved in legal and administrative proceedings and claims of various types. While any litigation contains an element of uncertainty, management presently believes that the outcome of each such proceedings or claims which are pending or known to be threatened, or all of them combined, is not expected to have a material effect on the Company’s financial position, and results of operations or cash flows. At June 30, 2011, the Company did not have any material pending litigation. </div>

<div> Note 11. Segment and Enterprise Wide Disclosures  The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 61% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2011 and March 31, 2011, respectively. Remaining assets are located in Europe, primarily related to the Company’s Impella production facility, and include goodwill and intangibles of $41.0 million and $40.5 million at June 30, 2011 and March 31, 2011, respectively. Total assets in Europe excluding goodwill and intangibles amounted to 8%, respectively, of total consolidated assets at each of June 30, 2011 and March 31, 2011. For each of the three months ended June 30, 2011 and 2010, international sales accounted for 7% of total product revenue. </div>

31776000

-8556000

<div> Note 8. Net Loss Per Share  Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported basic and dilutive loss per share is the same value. Excluded from the calculation of diluted weighted-average shares outstanding are underlying outstanding stock options of approximately 5,024,000 shares and 6,058,000 shares as of June 30, 2011 and 2010, respectively, and unvested shares of restricted stock and restricted stock units of approximately 837,000 shares and 653,000 shares as of June 30, 2011 and 2010, respectively. </div>

-4498000

2332000

5001000

-5443000

96000

<div> Note 1. Nature of Business and Basis of Preparation  Abiomed, Inc. (the “Company” or “Abiomed”) is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery for acute heart failure patients. The Company’s products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and/or in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophelactically during high risk angioplasty procedures or who are in pre-shock, shock or profound cardiogenic shock. The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2011 that has been filed with the Securities and Exchange Commission, or SEC. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year. </div>

15000

-4594000

-77000

7324000

<div> Note 2. Significant Accounting Policies  Goodwill The Company assesses the realizability of goodwill annually, at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. These events or circumstances generally include operating losses or a significant decline in earnings associated with the acquired business or asset. The Company’s ability to realize the value of the goodwill will depend on the future cash flows of the business. If the Company is not able to realize the value of goodwill, the Company may be required to incur material charges relating to the impairment of those assets. The Company completed its annual review of goodwill as of October 31, 2010 and determined that no write-down for impairment was necessary. Revenue Recognition The Company recognizes revenue when evidence of an arrangement exists, title has passed (generally upon shipment) or services have been rendered, the selling price is fixed or determinable and collectibility is reasonably assured. Revenue from product sales to new customers is recognized when all elements of the sale have been delivered. All costs related to product shipment are recognized at time of shipment. The Company does not provide for rights of return to customers on product sales and therefore does not record a provision for returns. Maintenance and service support contract revenues are included in product sales and are recognized ratably over the term of the service contract. Revenue is recognized as earned in limited instances in which the Company rents its console medical devices on a month-to-month basis or for a longer specified period of time to customers. Government-sponsored research and development contracts and grants generally provide for payment on a cost-plus-fixed-fee basis. Revenues from these contracts and grants are recognized as work is performed, provided the government has appropriated sufficient funds for the work. Under contracts in which the Company spends significantly more on the development project during the term of the contract than the total contract amount, the Company prospectively recognizes revenue on such contracts ratably over the term of the contract as related research and development costs are incurred. Share-Based Compensation All share-based expense, including grants of employee stock options, restricted stock awards and restricted stock units, are based on the grant-date fair value of the awards, adjusted for expected forfeitures. The fair value of stock option grants is estimated using the Black-Scholes option pricing model. Use of the valuation model requires management to make certain assumptions with respect to selected model inputs. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on historical volatility of the Company’s stock. The calculation of the fair value of the options is net of estimated forfeitures. The expected term of options represents the period of time that options granted are expected to be outstanding.   Management estimates the average expected life based on historical experience of the Company’s option exercises. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historical forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model because the Company does not pay dividends and does not expect to pay any cash dividends in the foreseeable future. The estimated fair value of all awards is recognized as compensation expense over the service period. Accruals of compensation cost for an award with a performance condition is based on the probable outcome of the performance conditions. The cumulative effects of changes in the probability outcomes are recorded in the period in which the changes occur. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies, which are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that any recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </div>

4500000

156000

472000

1046000

385000

<div> Note 5. Intangible Assets and Goodwill  The carrying amount of goodwill at June 30, 2011 and March 31, 2011 was $39.8 million and $38.9 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, or Impella. The goodwill activity for the three months ended June 30, 2011 is as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">  <tr> <td width="87%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,946</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Exchange rate impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2011 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,752</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The components of intangible assets are as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">  <tr> <td width="56%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center">March 31, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Accumulated</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Net Book</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Accumulated</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Net Book</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Value</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="10" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Patents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,379</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">860</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,099</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Trademarks and tradenames </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">369</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">323</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">361</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Distribution agreements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">704</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">621</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">690</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">584</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,433</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,143</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">290</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,384</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,014</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">370</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,745</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,466</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,279</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,534</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,902</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,632</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization of intangible assets was $0.4 million for each of the three months ended June 30, 2011 and 2010. The Company’s expected amortization expense will be $1.0 million for the nine months ending March 31, 2012 and $0.3 million for fiscal 2013. </div>

-4421000

-1360000

27166000

189000

<div> Note 4. Inventories  The components of inventories are as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Raw materials and supplies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,325</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,784</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Work-in-progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,944</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,689</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,610</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,032</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,879</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,505</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company’s inventories relate to its circulatory care product lines, primarily the Impella, AB5000 and BVS 5000. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During each of the three months ended June 30, 2011 and 2010, the Company recorded $0.2 million and $0.6 million, respectively, in write downs of inventory, including excess quantities and obsolete inventory. From time to time, the Company loans finished goods inventory on a short-term basis to customers for demonstration purposes and this inventory is generally amortized over a one to five year life. The Company had $0.7 million in demo inventory at each of June 30, 2011 and March 31, 2011, respectively. Amortization expense related to demo inventory was $0.1 million for each of the three months ended June 30, 2011 and 2010, respectively. </div>

18176000

96000

-1680000

-220000

220000

<div> Note 3. Fair Value Measurements  Fair value is defined as the price that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.   The Company’s marketable securities were invested in the following:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> At June 30, 2011: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="13"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> U.S. Treasury Securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,982</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,982</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> At March 31, 2011: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom" colspan="13"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,481</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54,481</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company records these marketable securities at fair value and has classified all of its investments as Level 1 since quoted market prices in active markets are readily available. </div>

44000

<div> Note 7. Income Taxes  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to tax benefit carryforwards and to differences between the financial statement amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates. A valuation reserve is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The tax benefit associated with the stock option compensation deductions will be credited to equity when realized. As of June 30, 2011, the Company has accumulated a net deferred tax liability in the amount of $4.1 million which is the result of a difference in accounting for the Company’s goodwill which is amortized over 15 years for tax purposes, but not amortized for book purposes. The net deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period. The Company and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All open tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. However, since the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carry forwards are utilized. </div>

1601000

4000

<div> Note 6. Stock-Based Compensation  Total stock-based compensation recognized in the Company’s condensed consolidated statements of operations for the three months ended June 30, 2011 and 2010 was as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">62</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">310</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,756</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,332</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,371</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The $2.3 million in stock-based compensation expense for the three months ended June 30, 2011 includes $0.9 million related to stock options and $1.4 million related to restricted stock, restricted stock units and the Company’s Employee Stock Purchase Plan, or ESPP. Stock compensation related to restricted stock and restricted stock units is primarily related to performance share awards, as described in more detail below. The $1.4 million in stock-based compensation expense for the three months ended June 30, 2010 includes $1.0 million related to stock options and $0.4 million related to restricted stock and the Company’s ESPP. The remaining unrecognized stock-based compensation expense for unvested stock option awards at June 30, 2011 was approximately $5.6 million, net of forfeitures, and the weighted-average time over which this cost will be recognized is 2.4 years. Stock Option Activity The following table summarizes the stock option activity for the three months ended June 30, 2011:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">  <tr> <td width="60%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Weighted</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Weighted</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Average</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Aggregate</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Average</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Remaining</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Intrinsic</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Options</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">Exercise</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Contractual</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Value</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">(in thousands)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Outstanding at April 1, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,945</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.27</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.30</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.83</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(799</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.51</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(109</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.59</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(52</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.51</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Outstanding at June 30, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,024</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.85</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.46</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,443</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercisable at June 30, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,565</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.64</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.67</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,140</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The total intrinsic value of options exercised was $5.8 million for the three months ended June 30, 2011. The total fair value of options vested during the three months ended June 30, 2011 was $10.0 million.   The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The fair value of options granted during the three months ended June 30, 2011 were calculated using the following weighted-average assumptions:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="80%"></td> <td valign="bottom" width="18%"></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center">Three Months Ended June 30,</td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align="center">2011</td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="bottom" nowrap="nowrap"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.83%</td> </tr> <tr> <td valign="top"> Expected option life (years) </td> <td valign="bottom">  </td> <td valign="bottom" align="center">5.30</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom" align="center">51.6%</td> </tr> </table> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock. The Company estimates the expected term based on historical experience. The expected dividend yield was zero, since the Company does not pay cash dividends and does not expect to pay cash dividends in the future. The calculation of the fair value of the options is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historic forfeitures may not be indicative of forfeitures in the future. The weighted-average grant-date fair value for options granted during the three months ended June 30, 2011 was $8.39. Restricted Stock and Restricted Stock Units In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="66%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">June 30, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Number of Shares (in 000’s)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Weighted Average Grant  Date Fair Value</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top" nowrap="nowrap"> Restricted stock awards and restricted stock units at April 1, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.84</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">564</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(134</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.88</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top" nowrap="nowrap"> Restricted stock awards and restricted stock units at June 30, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">837</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.51</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The remaining unrecognized compensation expense for restricted stock awards and restricted stock units, including performance based awards, at June 30, 2011 was approximately $10.1 million and the weighted-average time over which this cost will be recognized is 2.7 years. Performance Based Awards Included in the restricted stock activity discussed above are certain awards granted in fiscal 2011 and 2012 that contain performance based vesting. During the three months ended June 30, 2010, 311,000 shares of restricted stock and a performance award for the potential issuance of 45,000 shares of common stock were issued to certain executive officers and members of senior management of the Company, all of which could vest upon achievement of prescribed performance milestones. During the year ended March 31, 2011, the Company determined that it met the prescribed performance targets. During the three months ended June 30, 2011, the Company determined that it should have been using the graded vesting method instead of the straight-line method to expense stock-based compensation for the performance based awards issued in June 2010. This resulted in additional stock based compensation expense of approximately $0.6 million being recorded during the three months ended June 30, 2011 that should have been recorded during the year ended March 31, 2011. The Company believes that the amount is not material to its March 31, 2011 consolidated financial statements and has therefore recorded the adjustment in the current quarter. During the three months ended June 30, 2011, performance awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management, all of which could vest upon achievement of prescribed revenue performance milestones. As of June 30, 2011, the Company believes it is probable that it will meet the prescribed performance targets for these awards. As of June 30, 2011, the Company has recorded $2.2 million in stock-based compensation for shares and options in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these shares and options at June 30, 2011 is $5.8 million based on the Company’s current assessment of probability of achieving the performance milestones. </div>

-270000

7629000

-0.12

38268000 <div> Note 10. Accrued Expenses  Accrued expenses consist of the following:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">  <tr> <td width="79%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">March 31, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Salaries and benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,177</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,416</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,216</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,991</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Professional, accounting and audit fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">616</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Warranty </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">599</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">537</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,245</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,518</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,700</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,078</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 0000815094 2011-04-01 2011-06-30 0000815094 2010-04-01 2010-06-30 0000815094 2011-03-31 0000815094 2010-03-31 0000815094 2011-06-30 0000815094 2010-06-30 0000815094 2011-07-31 shares iso4217:USD iso4217:USD shares

EX-101.SCH 8 abmd-20110630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Business and Basis of Preparation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Intangible Assets and Goodwill link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Segment and Enterprise Wide Disclosures link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 abmd-20110630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 abmd-20110630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 abmd-20110630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable, Current Accounts payable Accounts receivable, net Discloses the breakout of accrued expenses and other liabilities that are not individually material for a separate caption on the statement of financial position between the current portion (payable within 12 months of year end or the operating cycle) and non-current (payable after 12 months from year end). Accrued Expenses and Other Liabilities Disclosure [Text Block] Accrued Expenses Accrued Liabilities, Current Accrued expenses Accumulated other comprehensive income Additional paid-in-capital Adjustments required to reconcile net loss to net cash used for operating activities: Amendment Flag Amortization of intangible assets Total assets Total assets ASSETS Total current assets Total current assets Current assets: Nature of Business and Basis of Preparation Fixed asset additions included in accounts payable Cash and cash equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Net decrease in cash and cash equivalents Net decrease in cash and cash equivalents Commitments and contingencies (Note 9) Commitments and Contingencies Common stock, par value Common stock, Authorized Common stock, Issued Common stock, Outstanding Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 38,560,747 shares at June 30, 2011 and 37,756,719 shares at March 31, 2011; Outstanding - 38,509,793 shares at June 30, 2011 and 37,705,765 shares at March 31, 2011 Cost of product revenue excluding amortization of intangibles Costs and Expenses Costs and Expenses, Total Costs and expenses: Current Fiscal Year End Date Deferred tax provision Deferred Revenue, Current Deferred revenue Long-term deferred tax liability Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Document - Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Year Focus Document Information [Line Items] Document Period End Date Document Type Basic and diluted net loss per share Net Loss Per Share Effect of exchange rate changes on cash Entities [Table] Entity Central Index Key Entity Common Stock, Shares Outstanding Entity [Domain] Entity Filer Category Entity Registrant Name Fair Value Measurements Loss on disposal of fixed assets Loss on disposal of fixed assets Gain on sale of WorldHeart stock Gain on sale of WorldHeart common stock Goodwill Intangible Assets and Goodwill Loss before provision for income taxes Loss before provision for income taxes Income Statement [Abstract] Income Taxes Provision for income taxes Increase (Decrease) in Accounts Payable Accounts payable Accounts receivable Accounts receivable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventories Changes in assets and liabilities source (use): Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Intangible assets, net Inventory Disclosure [Text Block] Inventories Inventory, Net Inventories Write-down of inventory Investment income (expense), net Legal Entity [Axis] Total liabilities Total liabilities Total liabilities and stockholders' equity Total liabilities and stockholders' equity LIABILITIES AND STOCKHOLDERS' EQUITY Total current liabilities Total current liabilities Current liabilities: Short-term marketable securities Net cash provided by financing activities Net cash provided by financing activities Financing activities: Net cash (used in) provided by investing activities Net cash (used in) provided by investing activities Investing activities: Net cash used for operating activities Net cash used for operating activities Operating activities: Net loss Net loss Nonoperating Income (Expense) Nonoperating Income (Expense), Total Other (expense) income : Notes to Financial Statements [Abstract] Notes to Financial Statements [Abstract] Loss from operations Loss from operations Other long-term liabilities Other (expense) income, net Purchases of short-term marketable securities Purchases of short-term marketable securities Expenditures for property and equipment Expenditures for property and equipment Class B Preferred Stock, par value Class B Preferred Stock, Authorized Class B Preferred Stock, Issued Class B Preferred Stock, outstanding Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none Prepaid expenses and other current assets Proceeds from (payments for) the sale of subsidiary stock. Proceeds from the sale of WorldHeart common stock Proceeds from the sale and maturity of short-term marketable securities Proceeds from the exercise of stock options Property and equipment, net Bad debt expense Research and development Accumulated deficit Funded research and development Revenues Revenues, Total Revenue: Products Segment and Enterprise Wide Disclosures Selling, general and administrative Share-based Compensation Stock-based compensation Significant Accounting Policies Statement [Line Items] Statement of Cash Flows [Abstract] Statement of Financial Position [Abstract] Statement [Table] Total stockholders' equity Total stockholders' equity Stockholders' equity: Supplemental disclosure: Trading Symbol Treasury stock, shares Treasury stock at cost - 50,954 shares Treasury stock at cost - 50,954 shares Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line Weighted average shares outstanding EX-101.PRE 12 abmd-20110630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2011	Mar. 31, 2011
Class B Preferred Stock, par value	$ 0.01	$ 0.01
Class B Preferred Stock, Authorized	1,000,000	1,000,000
Class B Preferred Stock, Issued	0	0
Class B Preferred Stock, outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, Authorized	100,000,000	100,000,000
Common stock, Issued	38,560,747	37,756,719
Common stock, Outstanding	38,509,793	37,705,765
Treasury stock, shares	50,954	50,954

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data	3 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Revenue:
Products	$ 27,166	$ 21,761
Funded research and development	189	241
Revenues, Total	27,355	22,002
Costs and expenses:
Cost of product revenue excluding amortization of intangibles	5,891	5,284
Research and development	7,324	6,653
Selling, general and administrative	18,176	15,753
Amortization of intangible assets	385	367
Costs and Expenses, Total	31,776	28,057
Loss from operations	(4,421)	(6,055)
Other (expense) income :
Investment income (expense), net	4	(2)
Gain on sale of WorldHeart stock		239
Other (expense) income, net	(81)	81
Nonoperating Income (Expense), Total	(77)	318
Loss before provision for income taxes	(4,498)	(5,737)
Provision for income taxes	96	243
Net loss	$ (4,594)	$ (5,980)
Basic and diluted net loss per share	$ (0.12)	$ (0.16)
Weighted average shares outstanding	38,268	37,086

XML 15 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Jun. 30, 2011	Jul. 31, 2011
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q1
Trading Symbol	ABMD
Entity Registrant Name	ABIOMED INC
Entity Central Index Key	0000815094
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		38,523,668

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 17 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Jun. 30, 2011

Income Taxes

Note 7. Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

XML 18 R8.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Jun. 30, 2011

Fair Value Measurements

Note 3. Fair Value Measurements

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.

The Company’s marketable securities were invested in the following:


	Level 1		Level 2		Level 3		Total
	(in $000’s)
At June 30, 2011:
U.S. Treasury Securities	$	54,982	$	—	$	—	$	54,982


	Level 1		Level 2		Level 3		Total
	(in $000’s)
At March 31, 2011:
U.S. Treasury securities	$	54,481	$	—	$	—	$	54,481

The Company records these marketable securities at fair value and has classified all of its investments as Level 1 since quoted market prices in active markets are readily available.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 19 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Jun. 30, 2011

Commitments and Contingencies

Note 9. Commitments and Contingencies

Litigation

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 20 R15.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Jun. 30, 2011

Accrued Expenses

Note 10. Accrued Expenses

Accrued expenses consist of the following:


	June 30, 2011		March 31, 2011
	(in $000’s)
Salaries and benefits	$	5,177	$	7,416
Research and development		1,216		3,991
Professional, accounting and audit fees		463		616
Warranty		599		537
Other		1,245		1,518

	$	8,700	$	14,078

XML 21 R13.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Jun. 30, 2011

Net Loss Per Share

Note 8. Net Loss Per Share

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 22 R6.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Preparation

3 Months Ended

Jun. 30, 2011

Nature of Business and Basis of Preparation

Note 1. Nature of Business and Basis of Preparation

XML 23 R9.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Jun. 30, 2011

Inventories

Note 4. Inventories

The components of inventories are as follows:


	June 30, 2011		March 31, 2011
	(in $000’s)
Raw materials and supplies	$	3,325	$	2,784
Work-in-progress		3,944		3,689
Finished goods		1,610		1,032

	$	8,879	$	7,505

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

XML 24 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

3 Months Ended

Jun. 30, 2011

Intangible Assets and Goodwill

Note 5. Intangible Assets and Goodwill


	(in $000’s)
Balance at March 31, 2011		38,946
Exchange rate impact		806

Balance at June 30, 2011	$	39,752

The components of intangible assets are as follows:


	June 30, 2011						March 31, 2011
			Accumulated		Net Book				Accumulated		Net Book
	Cost		Amortization		Value		Cost		Amortization		Value
	(in $000’s)						(in $000’s)
Patents	$	7,239	$	6,379	$	860	$	7,099	$	6,005	$	1,094
Trademarks and tradenames		369		323		46		361		299		62
Distribution agreements		704		621		83		690		584		106
Acquired technology		2,433		2,143		290		2,384		2,014		370

	$	10,745	$	9,466	$	1,279	$	10,534	$	8,902	$	1,632

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 26 0001193125-11-212464-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-11-212464-xbrl.zip M4$L#!!0````(`*2&!3_AJ'T%#3X``*6M`@`1`!P`86)M9"TR,#$Q,#8S,"YX M;6Q55`D``S18/$XT6#Q.=7@+``$$)0X```0Y`0``W%UM<]M&DO[.*OZ'.=TF M95>)%$B";W*R6Y0EI71KB5Y)62?WQ34$AN1L0(`W`"0QO_ZZ>P`2`,$7V`8I MQY6*)&(PT]W3W?/T"\"?_O$R<]B34+[TW)]/&G7CA`G7\FSI3GX^"?T:]RTI M3Y@?<-?FCN>*GT\6PC_YQ]^KE9_^JU9C5Y>_#.[9T'6D*]A-[58$2KZPWRSA M",4#^,C%6RW!+CTKG`DW.&4C[@N;>2[[[>+^`VO6&XQ-@V!^?G;V_/Q<%_:$ MJYI'$]8M;W;&:K5XL7]K.L\9Z]0;S7HO<>G>"UW[G#5'IC`MWJAU#&'6S/ZX M4^N;=K/6[C2;W#!:(\%;B;O>*\$#F)'90"O<;30:-:-7,]J/AG%NFN?-_O\F M1WOSA9*3:<#>6&]AL-&NX1TI&9P"QU:=#1R'W>-0G]T+7Z@G8=>CF5Y&RF$@ M==?_^23!-WY<]]3D#.9MG=;:,AZ7_0+DNQ^,'J?'/+1K=Z/?[ M9W0U'BI]SVPVNMN(T2.6<_LR;V88VCC[[?;#@S45,U[+$]GT<4SO5N-6JL1WV8+ MF7\+7,@9+MTGX0?Y=^AK.3>YGNN&LWQIV8$Z"Q9S<0:#:C!**&DM[]M]4_H& M,+X)Y_/E36/NC^B&Z$(.;7`%9_)S[Z$K.3=(PL\GOIS-'=0+^HPK2WF.V$^WZ8ZI$N.?3U"? M:K'>U%]\^PM4?W^K.M-L@1Z=7[F!#!;OO=G,S M/#<0+\$]TBD\Y_/'*]/HMVKPKP'TUOYEP.2?'QXO/QN?B8-NJ_$9=#]TI;[' MIQE/F"TL.>,.[.?-W?7)WUN]=K/5Z?1^.MN/#DUSI"[G[[D_';@V_KCZOU`^ M<0>\L3\(WG.E%C#ZW]P)14'2#11^BO3(5WS^]>$R27^M!>3W3;C!^.FL$$5I M)@86G"*A`][:'@93H8#]N1)3X?KR28#G]6;B@^?[=R(8CA_Y2^&=*,!.H]MM MIM@I2%N:L4:W93I*^OGJ;N@^0CZZ_11]Z^NGZ;L48P$?V_?B2;BA.`2-W48[16(^"6DR[T7``2/85URYH-]^ M0F/@=FG)4DFN-;O]5L=,4;V;HC7[4Z&P#ZL//536C*7E4Y$F]J,21XX`YW$(RLUVQE5OHR1# M,[%3KEP;C5;:?^E%,^?=ZF0LW9_"R9P^V3)KIRF[`6SI!IY:@`Q+M9M>QHTF M%UX7E@QF=/["B0PT@3>`0!!,Z]M2",'#N2L!=`5@P4M`@1,-/"C4"2!;\G"Y[E0G]?WH0F[4#<:N7YK M$UD97V#;$M-?W/D(N.3&?<_G,N#E&B$XA4;F\,ZG(DWJ+5=_`%8%X/$@P`X. M!3W;9K^7]AE;",F/22#4.[PS@=&YTV`9I%!3S[&%\M%"@L6!T=TN MS!XL/CK<#<#0<%_F&!*4'*9TF@TS`V]NQ=\*1E6IO_7[;W.1!MZ0=-?%E"0ZBK+:Y(>6H5\Y/?GSD"SQM#W#8 MF_U,=BR?A&PP#SAW(N&R#F]`1Z]>+"=$Z'N(J*;17`OR=Q-TB,I`*U/4V";X M;J_WVBL#!=CIFNVL&AVU,%"`]",4!@I0UVRVS-8FQU9F8:``C8ULP'"DPD`! MDFM-@#[=])EVO,)`$5F;1K>7-;5C50:*T-TVLXCGF)6!0I2WNIW<,[*TRD`1 MZEJ-=N8D*:4R4("D5K>["2M^Z\I`D1.J;;2-PU<&ME)XP,I`EHY-42'L7;O; M:;^"RL">%!^Q,E`$9)C=W/K=MZT,%#'27M],>[72*P-%T'&FC'*LRL">.OBZ M*@,%Y-SNM5YE96`+"Z^^,E#HI.PW&YG#^]"5@2+:8IJ]M+H3*P->ANZ-5!KZ-+RRK,O`5..O`6VJ87?,XE8'],6"[TVWT7T=EX!LO M#!10CTZSVS*.7QDH!KX/7ADHDD#K]#*YR5(K`WL*[DB5@4**F*E?'JTR4,2Y M=EKIP*%X90#LS1+"]J^5-Z/M&,X1C_E7+T)9TB]B2_U&X0<&^FMEP>W$I&G' M-!0@=[CK2=K"OEC\"D-NW!MZL`G*"3X!EZ$' MY#A05PZBG&&I/&2`[G9*LD9@H3F+2Z%_WKCK"<-2::]U.]V,%>RF*'N6^,%P MC!;B/P`P*97<=K-G9HZ0U.+9N@'5%$K68/`B:4<2+[LN)H3AD1Z43%3/:&00MF984=T0_:'.RX8P/KH1_.*%&'LJJB]" M="?\6^D"]@@6<`X(.%010*5GT7C[5@!&L;4_HKQON1)I9Y.!!^0L$_L@UKC` MIY.Q0@M*I)\-+I/[1JN;]JWY-&1.9;X@ZA^]@05\*9&7>2B7[+:1)GLODC*) M72Y=W)ZA^\`=,1RGL/T2V)>L>^FD[UX4[7&^94J0)7N41B?;`+*;I/R$U-*B M(A]Z(5PQ+E)[_B)\E$;6.VA9PZ=/$E\)<.VI2R\/0B4_SD3UJ5FMGR#H*KFQE\KU[8DI\HP)7%N;F+P&).![9Y2$([G0R M&[^5E.W^CD*8&_1" MVNV6?SAUC'8:?.50L&\F(4K"E4IP=ZUA9@,OBI<-H9J91\S75L](4#@.YBD!!BKNH`W:,^E*/T"M>3H( M7&FTNYGC?S^B\@+WXX+LO,ZA6A+*N/ MU/U!W-L2$)OP;W27@GT1!G=>\+L(L$^DY)`EHXG[T;1+"V-85WJVH&/N.L<2 MI*PC7YTWT^ZC[".LEC6+M>5W2373>E\N0.CMD&N&F+W2T]?2Y:YUN/1TIN*V M/U49[Q,]-!!W$UQP7UH8(DLG#+YQT7!SWT/-J#SG2C-`;Y5+A4AQH'+ MM:>BD'@9"U-P?)#PO#!5"68^"7P-I;`'3P!1)N(NG(V$(MXCQK^B,7032^O; MH1O\C%YGQ4]QPE;OX(M?)GHM?8L[^N"_AL\*6T?\J-W?_]70;]7;./-J\4?% MD9J'Q6SD%2C@9Q8<7-Q>ZB53\V7?,W@O)@0GW>".SPI[L,1J]+)-=G/W/OGV MP/3LJ[4'(`*;Q.#PPOJP7'0,6R_T2T>H]X`#)IXJT&Z69=&*7SIK M,YHQR6AJB4UZ]+O@ZNNT"'_/TZ/ES.M+/R[F7[ZM>"V]'DZWOHC6XRMP=OA. MWJ_AKF9T:BTCO69J]K479<(`B(UN7%N\_%-\^?9B$J_7:!M],_7ZR_3LJ\6C MCIR5^+^6^5K-:-5:T>YNFKWD[IE"#P9W.\WLZ^=>2?],L;<6]C,]@*^C?Z88 M#Z^L@:8@\>:1&VB*O;&GU\^$:&4TT!0BJ=EM99*=FQIH-CYJ=PF>QO%\B"\? M@@$[VSY].,D>%>MX!]SY@<+?`7S[>#^EYN[VN/PXSEK].8O M[UCTR<7P\7%X>\Z,^_/A]W/V*&<@T#OQS.Z] M&7=/F"__%(C(XSM'^`O$QH+UZRS!-`.85ZVD^,;A9Z/XQC-<<_G'?,4!OIT= M7]U\.O+L!:O5=O#6R6=M^=F'J^O'<];\X60USU=RB[](_.4#>*8)I>2)![GD M9C>3FUEYO/KML79S=WEU!V2;/VS$.;BCCJ91HM3+7QQ"&8G3=QG@/:IDP;VA:PF%%X+%*0/B(:*@2W,((>"G MLV`CX4@P.Q^(G_*`:/?"`/TNWB^X-65^"/]+TN>IF+SGJ81K$)```T*'27#Q M#Q?K?X$'D\.$^&4"PA7V*5[BCH/SPC(SL-392-(%D)+K!=6*`%=O(5*%>Z?\ M"=@$H@/`42`T01DR_(*$A'Q_Y+/YN_]^`3ONO_/96$?@W`%J/)^>D3HE80*W MH1.0-+UENQ2Q`4,PAV$+#_"5T133DPWK6,TVH%741Z2VUI([41@?#! MDL1(!-7*:F?J6W7W+'(XZ=;X_9U=MA8PP1OOQ1PK7.[D+^H=&XTZBUC5KO$* MV]OF"K`:^P38AZWX+M-1'L*[/*[4KEK1FBO0H8`5"#8*?;`>WV>^%L;*%LQW MJ*\J:L(XA7-WV8-1K:`]^-PA\YZ!00-4QP'2@IG![+CO@U="VU!B[G!+D.[/ MP]F<-'L,'H7*S-J(V9A++/6P*2P5U-GC)M.TIE(LC0\G0BR`K4%@/7\(Q=[8 M`C9QANY@Z3A@*KH+D+@5HI=DP_$8Z%1OF>VAQT(KU$Z-['`.),1TQ<;J"_@4 MI.8LM"?`:^"#/"ORFS`TP#QX M)N=Q"J[%2X=@%@9N9@RM]D3,BBG4:/Q`1&WU:X$4/F*XFY;KZ@O00 M(_#1LPRFTD4?+MBO]8B%0=[.HL[N MQ0R.#^0@9UG0Q*L06Q9.X7P`EI1T%C@!O1`%]W$C6S>SN7`*'6J-&G,+ MV_#T1E4KTL5G,`2;Q,^$(-5R6:XG_OYF-NH&F\%5G``'_,TTZNWX$U#V')^^ M6P8L+8)'W`*82_._Y)F)^"F1S33R&48`6A:]'S+"/25EW;R_@3Y^\_91GTO; MF*BS:[#A>`+(AQ,89XB,T*Y7#]N3'X#"--Q#5`* MML&ZD0(3']%V@@`)R1<]_?8XP;YMQL MKL_6"OY2L*)79UBZHQX?8+!:(1:_>H'E'CNB`!IRZ5)-"K6/0!"AC\7@B]/SE@E2 M1*()`G='GW/H[BG8Q7V(Y8+'[DA8//0)L"W8LQCB`E(H>;,'#*&8)-$'S%/'#8G80H8'&H[B6ZZXK M&_'@8^7H"1_OWGY,Y;NDYJ%,^"HI?8WPDM*/-1]!8-8X\O020_40#G_E+"A: MWZAQ,#%/0=7VJ=$T3\&3+W48I=PY-=H]_#1>;2?R)&"114)X(=1]TRM[(FP> M*$DI`4T=0<.U3_$8S*&XU^JF*$-RVZTT"WM1FP:$!4'-QE/SNWERK1C<,,W^ M6M/']_SD6K&D=BOS=/G1GEPK5AXPOO[)M3*>^2JF>6USO:'SN,]\%:*_G__E M!'MUI5Y$R:!+X5M*SJ.&?(1_/CZQ1]E>TKR#8?;F(5*!@-GQ(15,9E4KL0S( M;Q/KZ-NI2U2M:@O?+Y@?C"0H@JV_2[=:>8-08)55>?]N+=%R^0[S>,DAT13) M(6\1$%$B!H-!1<%\-B\(P,N2BC`']J+XX1S1%LG9`U"G<`)+^_5P1GMA$=)R M=5X0CD_+`TRRH(0!MP"M1![)LVG-7NC-)*^`M7^?*-'93MN06_(2_L&X0/;;C\!%[@Q_B;V\IVJ#<"W:= MZN0+W>DY'O8F^3'!T:R:;X@")H+V1X*$<8K$YXCI4/RQJ"$J\%BT2Z[`<&(, MT\Q`Y5T^`P@=;3)5IN93X7`0`.@$P*HHBIH"VF1*^@C*)M*;.QPT6M>)[)#P MFXK70%ZPYE3SI^!Y3AG]P.LP>HQ?41TQ-Q$NKHQ77S4F)R7%-!AM/0HC='EH MRZB+$3]6U7P:#CZ>TRZ0[*C]5F<#&@WW(URG6,_V=`H^SM2N:GOP$:7-@S@MZZ*WME=U M&:"&4(4.JY%LHAH%ZH!5Y,J-S`WBS(0D05-TN(@Q`2)JZOWK]IZ;K0\ M/?"L<0UF59K6M=9"M@7!W&HCD\K([?^$46!PNBI54YP(&@GZB5:!CR60+;F$ M)$[!&<*1Y_/XM,(S2L4%\V7,'5>4HSV.G#487)QSB6Z(,A@;*M"T@+O(W@WB M6%")>826A$]B/\:J!8NV;K6;VJYKW?M7``R!&.09K!0G?T7&/M@33;0;4\$''Q"@138S3`)C)&> M'T[@0L"6S6!6]%;OJ)2=.)H0"VQ;&JI%;2-SNRXQ057 MPYR]#B$X\U>JC-[`@0,+,9F(\JI8+_?P)018T%Z")6[%`#/."N!<6%G?$K;% MPL9>/BU^'592E2#&MLMMH/_9`KN^XEK,.*1L!+:5`7S#OK+XKIB,.KM)=ZCH MWC>F0UB/)9:M5I;KQFNF.]%P+ZA4$K&J06NHEAUIL+M3KB:$MQTMV*AV!4$P MP)JXS268>K!1NN\@)1YL+-20'&`PP62"NTH\25#GE$X2I[FZB"ETW7>4;/)! M!7,]]HPO[*C9V#!(<.+3XQ&/L21+O!U1["&T6MS-7*/=@(J.]WV-J: M4@.EV?B35$D_-DH5.(%)(XP@$51#K(<5RJC'5+Q@H@(T5@8."`+#FCFJF,W> MK$P_G%.I5K_DY"W:J"^43CHEPF2%89/"U!?JKJ]?+X`M1Q:5\\;R!?,7:JE? M9$P4TEF>XV#A)C)LJA1RW\,1"U1XL%8;FYPT2U3@C'M8=+,+N@(7!&1!)`%P M2$75QD@:=E1;!0.(NFZ7!D\]=@D>;.$`B*?E!E1QQ2Q.HE5JN6PD#`I5$@NA MJZ=&8Y@_'I.R56J*(U\2Y?+(H!36!*-:&O@F[!'S$LQX;H;?J$E.EUQ74R(A M"HB@=)!&VGIZFM1_U?'F+?8_"UG>^;K;I#$ M1!9TAW%'+=0+2N3RT@1K!+6WQSL[8F`;K4OBE-0^/94;`K-[E^0 M!1XNCV8P1X+@UAB#814R('44$I9HKMZI#"^I@LJNI;FZ%%/DQ`7)48\JN^57=G(#P%:32_Z'35I3,_*!;YR9=.UO9>^>2F2"X41)0HTF()Q4@ M`GY]0RMGPMZJE83!*F"I^H^/ZD@PYQ2H%AOZR%%#8^-P%G`%?#GA*A&*VK/S+60''$\(5`!&;L[4PD;O M00&FKEQF?VW>VE.?0-#J'32%\(&9#V8&K/,@&1CVH;'N]&/L+039<"#0[0C# MMW2P$!E&,XT#(H]*XU_(>`#S2P7IJ/:$-X]BKP%O@YH3A!D+#=S`94F;7$S+ M#$8]KFA@/0J.X8^1O%>.G8KTT0YH;/,06=1>I9"SECOTU')QDEI%1>_+KD^=PXR(,=T"T>?2S^JY1DW'9DAFXJ] MR*#"=M[J5RD^6OFW'_[O&AY*U4/B+#ZK]?;+F8WQ^@"":V8HLL;XNKRPK9`7 M>D(*=)`V1WGH9;GGD0X)3IRF0-"D.,J4-P7CPD4>L3L`Y M.8UZ,D6V;U&I9*0AKTOHVDOM;DN>A9T%P>F=E,PEI9-C)R5&1A-4BKDQ5#F+ MGPNT(O947Z1^P2/*A4N!=E;"D-7^2BM)?TS$S@2:*K3%JM?UUJ+K+*]0Q:WY-NQ%>[3X]G6VGYAW^.!E!@9P(WW/ MQUA?.H$XE)$W>KD0:CQQ27$.*#&9^2GO7-4WTU$*[].[X,Q=QRWN8;06KGSX MAR`2[R]OK^@/'T\YK$`_`M(?*EJ.?4?PW'TQ<_QYF/85*R&6'O7$/C/H59)- ME%(T%-'C`J6/\I=",-6;KVM0K3U5(-D-NH1&!FJN4
\2Q6H3(6XZ?Q9%7%3^-)00J"B".E5ZC^K"[&9'\\KFRMR-[N[^(YSU* MLNSM0AQ'>5C%-LFRXPM8PNKG'ZQH)H)S-'KCF<+.H^-VP0C-74:7%W'\.7,! M#/:=N@'.W?KM$E]=KSW`WOFJ=]$:Y6.W>Z/61?Q-/N9&!0BER+BL.0>"Y/$% MP-_JVUW4&_%F!SM<'(/^EK"GP2,X2+/`NOR%S`/]HS(^T_FJR-C'%/>U'%6] MCB*"HHTFOHO7PC]N;Y"UG^-5=Y_A5M/F%/=P]?'3N^M/S;987\BM^!QS[3`/X)R(VL[(>RLS?3MSF:/CW9.F]#IW<(_>ZK[$?AOXL M&<;Z-_;P]>O<,.6F\>1U#:VKCOHRSYN<&&R>XG.:W+EQY#UPV^^./1'NE#_SE'T1HV+_F#K$7C^@V3SG\[4O_NCQ"Y+9(WF M.YI()VAXO'"HUY2W:X3X@$(\:I==@G-=+EU+;&3<<_B[;GA/O[JP>K2-1E;@ MWU3A+ARH1;$0JR1B.RD_7&\K'M[$CO+LFFL2,E54W[PZZEYYT1B>=XVF.9JF MZ<':=_P(3-T7436[=K>-KLG;]QD#7CU)@/;ET5;PCIL.>/S9W/BTV_L_NC@?;'UTT3WDT87IUG2[YVZK=!J6URNQHEHV@=\[(29L?'(K`"GER5?AAL.I8\T]J*2XS#B?6EKK!5W*JQ?7IRL MO_$P'=Z5[W\]3>*:)6R6<%G)6J0E7*4=__MMO4-Q'!.\5W@%%9?P6>"98<`1 M&/`'1A08RAN=@!'1GD8]CZW\T&C-S3LK2Q[1X.V86Y5F3MLM"_,VJTL M>P>-=OOJ[.W`ZNV7C;V%#C7Y+)G#9TQ^U3D#0_SLL1FOJF-0C'B3WL!L M0B?`Y6[/<+GR7"Y?\*-A\@X*>T5`E.%RQ;C<-;[A"7!Y4/H(O()?+;P3F(=X M'*E4O>Q.\DPR/^-2'.ADJUTZS]AP>0?=9>R0ZG-Y9/S&ZC-Y<&'NF:K/Y?.1 MV9:KS^5.Z?,'%?2:'H M]GT(@G+;=L>%K+<;P[X)2:@L?R\:_4'ISOX->Y\?<=(UL9X59F^[<=XS)RN5 MY>^H<=$N'=K3L/?YVGG0*QU[*W1B5HUR&H9RAG*&IVJY^4K\9RT)S94RR.C?6GLU6AZ[6-9:&QL#7\T5:5 MIE<6KN;?L!`V(OM8=FSXM1=PBRI3C[GUJM-JYT:$(_&$EQN(\.[6U.7NJB+< M[58OU\A$!#9SJ<)%K[5LI67E0Y=E3\O';U<2/E]._N.<2YBG=_?!L_T9_]4/ M@EUKQEN1)]1+(O#[W<[PR^^W[\XLA]MBQMS@I[-F[^SG9A]^@0;2T:\807Z( M\+WD+.#ON/KW@W=IVU@C/;AACR3I!QUPIS=HYP;\Y'CRP[]E+@\^\7ON11PY M%?S&PX..N#OL#`:Y$:\:0GZ0^L?WTI_](AE,Y:`C[(PN/ M*Z1YUW'^C$M)KZ1-^G"TNJC:][IF;ISKW@^YU6_5:_$5,QD,J(VZ*2QM%[OKC,6.C;EUH[$\65C]4187B6%LE9J!B91=A4397]B#]:, M`3\%F-8J2UX0S>>NJ&R.O./62&_TN@8O4UGV=AO#\H6L%#I6]C^^_-H47G,N M_3O)@ZHJI8)$:#0N^J437\/G'?@\&)4.]U6R-&'OA2>"*7>L.SPM-6KKL$"9 M3NE"RPR?=^!SVP"BCGC=7850$4.W/8`$GG`2RJWKC@SI'1E$?G79.VR#!GP6,R:%^TCXLP^S.7==UK`NK\Z1!8@QN_KCUL(/+2OO MSM9K^.M#>C9G\R`_%-OW`A&$"+-SA.1VF-PR-"R7C7VIFO#ON9QRYK2L=Y%$ MQ-LZ;)ZU!II'<+<4F]>@%S6A@!XV`B$*]=-L'(:/#>(OX`V)`\0N"?NN?O8 M@'E8#U(`(1W_P0NL#/J$?K3=B,!Y_!O.NE[[*V)>*$)"IN"4QF!]<7@[>6DS M&._(DH6(*2N$)T!LZC7\(T]#UV=`@TF._>G4+*2G%4Q]&3:!O;-Z;R;D?:(*%4Y%M40!)[[C')7-!,C6.DBM1@;Y\ MCP1\`KRR'CF3EBLF/`?)M*;,P2O%UC!A.7`4!Y#IA86)J*V'>]9KJP&8\/^L MQ+2LRU5H3[4:':+K0N\:EMIY%BQ5B7Z]]@0L=6%,&V5N&0"Z"2"W`$8$+0'B M_XMBT:7G7#HSE`[B[3V_UK,_+/BO,UR`)SYK4$N@4)#/S^R;_O4*7IZ(PP(K M+_+#7C.$_#C?LF`*,$_KO^*!&RHB(J[`67J.XM`T@/C6`>C/(YUFZ$]ATR,<:6$H)@+4TK7N<%FVS#B@;#W8HV(UPTP%[T,:M!_;&!S]R'0Q5`!.* M@P)UDC"%`$0"=RF&Q4]0X"WX`1<%[LJ@;KU@0ONT*]A8N")\Q,V7>18A8-'4 MQ$>8K:JGC'GXP+EG88U&:&G.8!>UQ9S0XS`*[&^64M]R0$;)%&6>+3#404=Y MX!88]T?&)Y-@A#K8Q"2=,9K`,$:8E.W"BV(B*%`#WG64(,,;,%8T,/0NK!#& M:.NI_=B&_N_(OMT!=/QR)MVO'"P`J_.C]>_(IV"4F+S(WX#X05:")KLRT(0# M%!8V<^/0&331,T0MM!&K9MS]L5[[.`ZXO">/3L\:#%)B[#RB28&R]--G]-OVAQ6/FU$41@@S,,Y%*[8I-* MQCJY%I6V"6AE<=@DR[(Z,#X.?5<>K"%5(B5$+<>*`E1],]_AKE('/EHY]*OR M=&8\G/H.YJ]'$J`/%O#X>77@H/F$73O@#\K'9A`"_9ATXN>H4V*C0VV#Z1@% MJ(.BV1P["1KQN$D/HZ-*PVM8CX+#'F5'\AX^W/O@;*G]9@+:S9=TO@'6VB/. MK5X#SX@[\!UL>2QR0PNE'SZZ&*P6`'W`WP?G'AJ3N-%HH2`7$`T:"4U&0"TM M)?%>&'FTI^'`5E*T`?.HUQ[`-T&94M0#KY#?PP9G<6C8GPD[WN&`@+?1&,D3 M"N7ZPFL8U1@263,4(=KF%KG:*6G0`3_%>E#3+/N"@WM!$_3(4]I?K)\=ZM!L&_<3L*U;ZY,(02K(@>&4$8 M:"0%:87)QLTA3R<0M1`M(0DZ-=EA:5\%2ZMVRH%U10W9DN;U)N.-4R\W"%IG\ZD:YAP?";T#!..P(3/?LC<(U*^2GO- M6N9U^B:"LXH1G)?A.E3$9@^C"!"^YPMO;UMDZ4N%N/6^FX&_MVY;UF=)IT"/ M]=IMXD$6GGTE1&">]QL7H](%$1C^;DE;4'_]_>R?AO.&\X;SA>9\.76Z@=47 M#!QN*&W(.86I-P[B[D%678PBW^/L1QM9RXRRGN1$9B+C,,>>O5'G:U'8`XU M2\)?_OY"CY7EC6I,N\;-IO@8MBPUPWH-YECZ@GEQ M0AHK9-_69L50B\'V[SS*IQ4',<,J$S/*!3")4#I4&QBJRO^*N&?3P@VE&$=J M06.:#_;-&L?9DIB4C]#6`\/E3_F\,-^5F,"(U-MQD@_*J)&$Q08A]$E9/=B, M*E]24I%DY+G<$SI-&!.RWM*'`!D@NFK)&@"511^.?.A35=\Y91#CWF47T'%"Z,FDQ8#Y82I MP:A`+5'`61JJ*@N+;U*^%=B;@#TJHQFQ(J8T/.P#Z7"\#R*.0622X_#;ZLQ!#9]*J?R_(:WP&Y`&3 M!Z"D9F5<[3P4BDVY`/3*6ADK?*]++2!WHE! M+E6>NX#6/<-<>Y16".2LZ5+F("7DN(2!BC1Z3V7YT9(H,?U"P),(Z8#-N#6G M'&*%%LALRD%2-FBV!-$X$(Y@2:%2^.)/3'\)$Z7S\0EW,$4=YI'T9[3",4N$ MI9-$4*X+_3V*&4AP*.84JXV9/9&(P'$.UJOU)YA5@2/4&L\E0*S7%A=`-M0? M4U[PE'UH-ME<*1#@0.=BU`$EZ+KUFC]'I0WC4-(H^0RD)#L?_HW-0)_3JY1' MYD\EL/5:;FS9G)FT!V@*W*&T>VH+4/J=PNMGOO<`^BBD7(C_`N%A]C0""0IA MDO_T'U!8&GKTBVO>0V'VXV+0*KD'-0V34+IO8;M2:W#&'G$U1)@_Y+^8+`.F MJ?="-768JUHJV)).#8%<0JV#V6744]@,&&&880J+J"5D`OD6($'CQS3W!S2# M`V01O*^-8Z&V!QH?9@F(-U29#FS[G([K;;BGLO%]R.=R/5PJQT$[7\M[XU"6 MBSHK%T'-]-!5L?L+`UWJ/3^\E.H?)V\S6_,GE1?TK1^$P>T4&'R%.8EN5*:: M:F72&[2L6[10FC1%E3TC)D/)36Y":\`ZI^FIK%(Y^RMC:6L#8]7.2H:V@TDD MR2QB98OR>-5M]>JU3#'E MM:B7N/9Q#J6BZQC7:QM1*DEQLE?MUD4"OTV+**M.$=^GZT]A&>].J[_J4 MW][<:(S3(OQG[6"4C[[TK1J/"#)EV3.-S+D$F@)W;&X%4RI5R`@A2.A1()LM MQ5AAC0B4[O"0"01]N_Z#`H?F:(5783LQ<6,QZG:&B9U6>RT3-6!=EY$'?C^+ MB3F4Z`IF(2N6]Y-BX845B%9X=_5:Y&4@8L_B1137DLJM!(MII.B*//!J91'L M:SZ7_C<*]`#!>G7>&L0D!T%&L#@64/3EA*L(H4:R,!XH-QUWFNR>2W;'50D^ M`JHK]"R6;T<86Z`#&<:Y*!.0YRZPEQ"RNW!G#4IQX2!-X[.^ASOX9G(++/"/ M6T7ECXK*E[JT&PU;)!-8#J:8+6-;KVG<731##?-?'BP'D<0E['90 MX=4$%!ZBHMF@O36@<'`<0*'I=F_=G@1XIWNLL1^_R6H282_D.`R@ZS_:--FT M$5>7ID44,:/B2K:ZS9HNE&`=AJ:7RG,S)-TC2>_N)+\#9_J(1#7*MD":L93* MUBB&O9/T4WS`9XBZ/Z)^\$(IO$#81MN6DX'J#'5CEJ5"KHG"$?+Z&Y>V"(S* MWB--W\+KDMEA=-3J"Y4C*Z7,,PI[+\PK;D#L#\)+YQ%._2A@GG/4H,K#-%E< M#MQ@\LO2T;L*E/_,Y2R=R`]TQUT^R:\")XJGA4XJM/MC%`8A4)QRFH76Y5P* MUXJ+]RS3R80?[0W6>]ZXZ)]O/8!2HK9?E+O'Q6JW6]WA:3#UI!?OH-4K77SL MD=A\P,<*G9W@%\F\^#;4[*&'68:]TD5VEF`#+09K.X/6J'<:W"VRBJW>C$J6 M)B*^-C`;R2&US0_#8R<)^(?90?;,TXO6>>G"9JNG;JLWHT)['6\QS-!US79Q MV.VBTS;;1<5XVNFTSD_$G2RR=JW>C$KG<,R%-/O'8?>/\R/GZS';Q[Y9VNT9 M=Z,`RK9Z,ZI0)J4JY+1[DF[''G^YJ&7H9NBV1[H5^FPFC[5:5P_7&-X'!5VU MN_W3L-)>E+O'!5UU6J,30=*=].(=M/HF7WME5W&OT^CW2X?X,-Y9H>P_XYT9 M+\/0K:AT*]U-"$&O*+3'^&O',0H:YX,3,>U/Q]+KM%N#$W'"3WKQGK<&)A:J MLJNXVVYT^J4+@JJ0OU:-ZAHOY[&="+T,Y0SE3`6ZJ]=T*1`G MDG@3N+I,RZ:"(*_`@&XG17UV+ISR5.V&9Y1N6%\8XJ6XJ^O)U&M`4RJ1HNIB MY"G/F3W-E\JX4\&YF/("'Z>/]9H#[UM1$'/ERF7VU^:M/?5=:%:_B8VJ^BXS MW^&N8G?:7;V6$:RXEUTX7:\]<,DMF[EVI.KJI`-+JH(LE7BIUU@01#/5?S6+ M>@P'^R_J,=J^J$=GM%W!"9/3;':H7$ZXI-+1_XO65OKY&A<9/2RMUVH:2RN. M)CE.IOM<[\$P<6],3$Y2M^7""R5HVN"^OOBY]"<1?&U.HU&2MD:]OW__,CUF?`6GRGC:H'#%!+;M;`JZRK/P_,GL.:6[*5(\ M!=O>!V--N'&UN>JSLM,:;+,:R^8]REC7D@=)RM9"78O5$57-1UC":)/_WKH% M7T!R%D3RT7H4W'4L.Y+WJ*0M/IF`?(!QKMP-58=QHOP#\C&9!6W/P"X&#Q6< M0P\+,H93>IC'^D(I"GAML?!?T++^2,3.RC@`%LM[$#1@:$*->`H]^5+`[U8J MM99N?V6=3NJ4/)ZDD*>5][N2P=)T$@)ENL(GI.">S5OUVN?L*XZX%PZX1)IX MZ.G^ETN_`3S!TJF945F.#_UY/E!TSAYAAL$T>5O5A8T?T*U3&=;E)X6GBI). M(JR"`$J@!GZG\ZV5J<+>M]^H&XD3Z6$(=Y6$R5 MN8_`>NQ`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`EY4YL+`*J29,(IB=`[Q.YG`6K^PL MD\;C!93]J&<.9RMV.-LY+V&^\PIMTM6(+#;1_R<4B2WYC`F/,+B1)[GMWWGP MA&/9_FS.O4!AKA&P[04*P;L,I7QR7V]8PK/=B'(LS[F$5F98$4NCK=7[C0W9 MO`COR^9SZ7\CG+;[2.'6G20B'-&O)O`XYCJ(,` MLHH@B.@!:*=_C@U#&TG+H$Q@3)J!%$*/SZN0B9AE_!NW(QT-,1'P+6*PH?\9 M1RP7-1-P3T#/,!)8VC,,R,D'QH`.@34-WZFU;ON1JWEH17-4$_94\/ODS3F, MSI9B#./(3A&4"KSA>Q@I\BX3GH!:0=/T7TS:TPQ1-98D#W!W.,;;"`^GB6(F M0+_-N`HV6M-UR.0=#W=2/442M\1_>YH@P1299$U!7X,RYEXFH0*L76PP!MP# MZ:8^KN0@1&"3XCP*JF2H\YLN-!P_!&(5;UDD`K.HM'@Y%$^7VLW1HD64.``CA3W)&D M\ZP4%5::F8)(ND3.56TM"C*H`@V,5<$,,;_&W,7E$BAN41C#S(]`9H0*X\(I M2%S\0&Z!(1-):TK+8N`S<)78"I)46&UCLL43 MG4.6WXP_2Q7']`TPBPLQH]`BMP69<-TEB^U5M]5-K&E4:AO5IM[8 M8F"C2GUJ9\UH*"T3T)1$$PY?U@P#"5$*,7Y$J:?$8['6.BSU6JQP)5=1MBHV M$_>#Y;'K4\=5Z7[$0NJI7'3QRG#<6$$QL$R#0$MZ/*DDFE?-*%;(:X1^\^FG M(^[QTYO74="\8VS^XSLP<%T_B"3_.'F;(<8G18*WX/0$!'PG]^"&/9(._LR_ MA5LVRWL2-@1V.8=/\'5?_?O#>\0F'J3F?]$I%JQG>_<0G/YUQW_UR M<]UO7_2:\%^GTVDW_PUJI_?E]O.[+Q>=+TC,]J#7_M(^([5%+XG`[W<[PR^_ MW[X[`]O`ABW1#7XZ:_;.?FYVA^BPIW-[2?<*"39 MW]\DOH`T?E&K)#N?+G`%7.YN.IDG!J5FP,8SY\<8U:^Q_"HZ@Q[7SZIXC&PI MIN^>T?(,D".]47:TT30`S_XAVS*]"K7-@8KHBDU6V MZ\1^QC6OE_P.)Q#?>Z@;'S?\!E:&A6:PGGR]%D__F:<+>#SV;2S=QG@Q_."X MYP[)?/3&$<1I'Y)\`W&$KXG;?6[<[O!BZ[C=\^.$[1ZT6Q/R]Q*18]NDC]MK M/-B1`TI/E^/+AW`GPO(J*907#PG_`;W;5T6*\3U6".<*H^7PJ*!;YC(IN#Y/ M&G./3^)<-]7#^1P5"W+>Z`Q/!.!SBNP=-OJ=TA7>+'1LP2<><+K`(-7D\'ON M^G,\(ZNH=BH&"K'3Z)9/C@V?MQY%KW%Q47IH8L&-JQOI3W@0T%UTPV*VC;>U MA%\@($?DB-":<%Y5LN'RUJ,8E&_3*K3Q]1\F$:I7W`3=51#: M\XO2)4HP7-Z>R^6+ZRF9G47WO$93'=8K[)](B>D3Y_-YI^P9,LHVBVL..IXFK$$!O*[64;6PRP M3E'RNT-V%>17XW8MX6R'V\67X76,S0D?]2?XC,6N0C$1'-:>/>4SH-DT#.<_ MOG[]\/#0"KC=NO/O7[_]\#]G/R/Q1IWS]D7_S>OTM;CAU[F6WV`=+]])^PE" M)D-,C_XS#JK9[C?;G3>OTV^3![GG9!X;-'MM;-K)//3F=:;Q-Z\U07:B3KN( MU&D_CSKM`U*GK42GU^L4@#@8:+-N7WH.1=%1>3Y MK&3[<'PNW)S;AYYSISTLFFP#GX=;RC;51L,)Z\":^)49%=?D/ZNOW[R./ZLF M\*V%][/Q4HN-Z-]^A-^V:RD;M!0WJDI*IO/']WZ+9ERRT)?)U\_I7=%F]?O4 M[#ON^3/AK6MX%6W2-I=??O,Z,_9DZF]>8^`,_/'_4$L#!!0````(`*2&!3_3 M1VMV_PH``*2,```5`!P`86)M9"TR,#$Q,#8S,%]C86PN>&UL550)``,T6#Q. M-%@\3G5X"P`!!"4.```$.0$``.U=WV_;.!)^7V#_!ZWWY0Y8^5?27!,TNW"< MI#"0U(&3;HM[6=`2'1.512\I)?;]]3N4+T(+Z=+:T^LAS0@\%T*UU0_QO8\3Q M;Y;XU[7@HZ\7HQNKV^Q8UC0(YF>MUO/S.`_5Q#/ MK)-FI]M\O_67$0U]]\SJCH_QL8,Z]DD;']O'IY,3^_38[=KO3KI=U&X?C3$Z MVI+J,[P"YP)LD&YW.G;[O=U^]]!NGQT?GW5/_[O=FLZ7C#Q.`^M?SK^AVJ"_&S&M2]MB" MOH]:<EI M*_KKJC4G9SSJY88ZD6H4`%K2%N(W.VYFBX_L3M<^ZC07W&W\+@;\P*B'1WAB M11C.@N44B><83^(?R+?O?(# M$BP'_H2R682^88G^/X\&&QI?OGQI]BX&P]NKRV9_>-L*UG.U)1JVE/IL'8I\ M!))_W0'[(LB[HYR((?H>XIQ,"';+$E#L]7M2N$,,E_XB2G0= M3'%`'.2]/BE8RG2&>UZ`F0]?_1,^@,5^7Z\.MX_X]-JCSWS@NX1A)S@`[GY? MKP/W$PTP?Z";[W0S)+\(.=A/SB\Q=QB9BR^ZY[L7B!,^G-PQL**P',6G#W@1 M7'C4^5:6WJN.7;4Z[LFC#W/<07[0IFN3`?X(?E"V3T2O@F#M*U10_4NH^$\^#9300V^@C M&7NXQSD.>*6D2XY;M1J2,<&DTMD<^SRR(R,,7C%V^Y3#RIO"+G8A?.([M(RD M*M#+H4"J7Q)B>X3`H>(ED3-*U12O$//!IO([S")-5\!//D35Y&!.S4@0_1>6 M7I]&VP?$D+!Y5/J-EARW:C7`ULE"[%XMQ`+#`M(0W%-V0]"8>."\5JR-EPU? MN2N#'\7/$9Y3)KZ>2E6@,MB:L)-D)T1R(D4)2#`TC#(`"-)4:V1,)`M&*Q76+"+@V_;1G`3(DS&2M-:"//*^94!7?]2'JV"VI]KH0"D2 M,<*S@1]7?X=@,KQHHP_ZB+$E[&]1%"M!KR:KA16X;=2_#V`WSB6PVTP'UDL\ MP?#]NR,,\718L#M)&NO$#19KRUI_HKZCQ$`JIH-+'-9+,&_^K`/;;IX!MHFK MA>.%XO2L`+>2J!Y.Z]P1())BWVJB`^/6[)1`W&ZA&2&8X`-?$,;Q'[A@/A8-]CL%P*P/,D=##8#=T++7>.@`[\=VR]DQ1N M\UDM-2&>@[N\3I_$V1,5/U%%4@\C.LCLK#.H@Q4'-4]G;3; M#>L9B\J=Z'?X;=[H-JR0`S@Z7X76=667O^@3LO]Y"V35O.^$]/NW M0#J+V*EIQ'9VU&U^BDF/A'SG#9'/]5P3RMTW1#D_D9YP/GI#G-,A=L+Q^`UQ M5'*H$^KOS*&>D7S8)IX5+6]X=@R:Q@4\BW.,"6N#)G8!Z[S(/.%KYFS.351) MIO@V:X,\Z)>PSFJU(=\U99#A5J.? ME:=,Z*8LMOT6^):N?4J4\1);7L=BQ?3]+[TP]R]XZ:AIFHFJU_]%/`6D=&Y4 M5N24+Z2G/HB#2D6:D]_#.I"6!Z5;Z4(JPH>XYCH':JJ9EBH:V!Z$21CZ]\C# MPTED9P;^?3CFQ"6(+8=L96YN<3"EKLA0\0#+CGM>VIN>>I;8'%Z#I5U=$PAA MCQS.Q8UUF/?\`D\HPYL+(IC?$C\RB+`>,`/DT8VB[5[VR44%Z-)RF>^'0)^& M`?=ZAE]@'WP.>?%0=FM=M4XKS:U0Y9<\[;;4@1C&32:"!&NZC1:4L$^N)K?_ MN(*R_K)EB*7MM53?I*'D:#JKI;9ZH;)*+Q#24^_!,7C+X@#P$C]ACT9GU_DT M\F7TL(@2*<),?V1(OB_LM].(M@"D'FS"N^!K!)&O)S?0F4VU8,:>)PH08%MC M2%Q&[KDSXA,>L"@TR)_,BL):0U29VYM...TX\48>9& M%EBI**`HWC:RV$I#L)0Z7'0;D767B+`R)/N4K1?G!4T\CB\E&J*0FHC3\=S,AMIGS8. M"8VLOU1DN>_D24K%:V[H=@/XE)>>&4`;63R=1S,CXW)8M;2VH\3]AR_6YL$# M=QBT)EPD<=B.+_'JI^S0JTP7.J_(ESN\*)+2PV0.$X6L5B/$X5MQJ92%7$(' M@ZO)!&;Z<'*U<*801>,1+(>AGSV%))1*=5&'`]C43:W--2W%\U:)=^EUE0KMR]6`3 MWXTJ\]5LR]2#Q?KV4ZSBS%M0RO24.M/ZJ)@OX$SC2_HL M3P0\]8OE9RY03E^^P_=%9^(1STX&+O1 M244\]C5E:[]YXS!''O0.Y/+RFAY@LP$H4($*;U$@YLAR."DSYTKWHYVMT/DP MRDCQJP5F#N%85@A=+*>)S1,1[VN"&75)PW$P";TX*)`3D8MH*>39/!-_^ZGY MLL*=[,9ZJQA>D,9+'2*7V&Z-O/M;GF0>JIKS7:.3%[Y=IZ061 M@Y$WQ5]Y>>7$@I)+Y6:NL9Q,RLZVGEV@:;X!5M1`[IFKD0]J.TP?^?&>D55$ MARE$%CP:>0_B,%5DG1(8>2WB,#6H%@!(+DR\Z0VEL!C'R,L4KSM?RM?F&E7% M>*B-4:E>D-PD^<$TDSIAE]2X_V`J43NNEQ2]_V"ZVBMR,K(2O@*M[!46F7K3 MZE45LU>==-CEJ>];F/VJKXVO%7[%=[[7"G/^F]MK!37W!>RU0EKRK>FUPG[H MF\UK12;W!>6U0BI_U7BM8)9\/WBML+_L;=ZUHJ#R-FXIX`\M`60,RQ9^^0=0 M2P,$%`````@`I(8%/ZH^868,$@``WSH!`!4`'`!A8FUD+3(P,3$P-C,P7V1E M9BYX;6Q55`D``S18/$XT6#Q.=7@+``$$)0X```0Y`0``[5U9<^,V$G[?JOP' MK?*R6Q59\C&S&=W6"_((=IVK]NE)K]U"CNE:V)E=M7]][/0? M;X;#]L\_??>WCW_O=%JW@U_ZX];(L;L/./?(]_-;ZW40V\@P?M9Z,-]=Q MY\O6`$VQ@WUHM?4).W].#()^:-%_6RWX]/OU^%/K[.2TU7KV_<5EM_OZ^GJ" MK)GA==RP[1/3G7=;GO&0T9(G`540^W>Z6FG]V.G]^ZI MU[N\N+@\^_"?S=+N8NGAV;/?^H?Y3RC<>]>A-5+<^*$U=,R35M^V6V-:E+3& MB"#O!5DG<4MVS(<6L-PA5^T-Z&\3SSYQO5D7VC[OK@JVO_M;*RI\^49PJL+K M^:KX:??W^T^/YC.:&QWL$-]PS%1%VEA>U=,/'SYTPU\W2P,=EK\NODG6NV[T M8U2:X$L2]OG)-4-&?\].2-6.V?:(_;0]*IM3.96.#B]]^<]6O_[@6L&<^3XJ[^&8]TZ M/O:70V?J>O.0^G:+MO_K>+B&\>7+EY/^]7!T?SLXN1G==_UX8G=IP2Y7F]U= M*1]#S:^//LQ0VL=H>H<=&%ULV`\N"9?6C6T0@J<86:(`.%L])(0'PT/"`R'0 MM/^,?&P:]OY!P<)WYZAO^\AS8.A?T`XHMMO:.[DW!GF^L]U7,G0L["'3WX'< M[;;V0^YGUT?DR5V/Z;I+GA!![KO6-<&P60T??!@SX7E2+\^ MH3?_VG;-/T7A[;7ONMGQB&<.S''3<+Y)!P'QDC&XI8-RZ!E?<,4NR::M`/ MQC*L50-?=B6D_B5!Q2-8&34OB8)>ZH9X:W@.[*GD`7DAIVO`Q^ZB;G`PI^;8 M#_\3EMZ-&XH/,#A!>-0ZHH+]ULT&$)U>@*S;-[K`$"5I!.JI]PD;$VR#\EHS M-ZIU7[LJ@V;T[Q@M7(\.3ZTLX.DL!FQX)B]FAH6[LIVI:?LN9(5AV^U6W/`F MG'4M[/A="\^[<9DNK5`C/=`53`78Z#L6FAJ![8M1MUW],+2ZJVU$Y#Z`%,TPR)#CD4= M%]%7VM0^G2\A`4`"+.14OS;U5[E>+K-"B`29)S/WI6LAW*6[%_V/3N0?/(U= M4M_#IZ]]Z-JBW=_9QFS5G&U,D'W5WOZ]6SL]-X%'G1QWL(\9]A_(\&X=:P"[ M70YIS*+U4[D:LZAOT#^P:]W!-Y)#)KOLH>FD/.*C,BEY.!HWICTL,S0$"5=$ M:&[QPU$;C2-[Y0TPP#/L M(6S<;_]&2Q9=6^4.1A]H^:[SZ(/R%MHU9!3X]$2$GF:QB2VJ="C*![$FPZ!Q ML*FJU$_-';:1=P/K;N9Z[%%.ESH4;6,TPP1FE^-_-N;,I9$M5C]UG]#,L*.^ M^V\X;P/.EJB?IB?/H+/X<3F?N'8.1>G?U_0D:EO?2U,&.M^JF5C]X[-7M=R/0MY5^W37N^D!_]`Z5"CO:3F&[*NVCZ8MLE'L/1!U;RU M0ZL/5.7([&NW%B!=/!B)J_99NQ40P.&&_GRC-CYDC(%=.)*652N&G/1.*3L: MC2RC52?0SAH/C:$`)1#/CP;BEM:<@+PX,I`I$R:!^:[Q,#.R(X'VOO'0\A6) M!.&_C@3AEKJ>0/RQ\1#9_HX$Y8?&H\S5Q]<`3WM'`K#8<$OP2E)PZI%]0%+_PR24$ M>#R:/AEO;$Q"K4A!:EDXVCH>#&P-G1MC@7TCZ\XH*RV%\C">B$5H]*,\NOH3 MJOV:S.F>+B2/SI)5F2HCG4HNIF;+RJ":!N[22!CX<_N_`#9D.PP,\6\,SUN" MUA5&/3)0\-65@HH=YL/"4E!#%H)8$RX<@FPQ&;0.T!3!3+;&Z`4Y08GVPB@L MDVZ0:!O2_+/KF%P(F-6.Y;"H.F=78;4,#JY_ED%;-LX7E)K;-],.J(U90C=7 M53F8XMAMH(A)^T:1XSH&J\ZWC?7+8-MF"D=!!1GT/WBQ'E2JI.:5E$3QPL"K\\I>/CSQF*?)CVK*O'3K0^N MSM0+,>('5RP0$HSJQ1CQ8^0SX!.LZH4:\6/-PZ->3)'HXMM$HUX8$9=#?Q,4 MIP\]P:Q>8)$PYD+[*T&J7GR1,-+B,^X$JGI!1L)0TV[$-;1S]<*+A*%QV7X) M8O4BJ,7G+0N;+/U&;J"1C+$2=7AN#E^1@T[E4G$>E-..W_/\)[M6(,R7JQ MD@%65]?D0\8OKQ+,DG3,TJLVQ<=7"M^WX1E,$44B]QP^&3]UU69Q13D=$)M@ M5%<[%L/(O.*00%57&1:#RG/JGZ!65P$60YUWIIJ@5%?Y%9S&HG>2$B?ZL6S* MA?;<&9\ZK-[5R'3^?+FW(H"6D1>2;84+:97#EA&DP%-3\CV/Z,9S/_"?85[\ ME0PC&\E6#240#`D)^*F/2RM!.3M-&%>58[GW40,U7\_TG8-@OW]C*:NE(VN.)I$U9(=%0,XC-*UE_>,`J\_BF&M[` M^(!]QCN`_)2/2#N:]^N.Y=4$FA#N407QMH[0A+".ZDA76D03`CBJH\Q/V:5P M^`8?5"[70Q,"-H3A%BU3E=W1E6!NKU&5?<^5(#(6J,K>9QZ#1N-IJ%,&3J/P81@"QO>/8.Q%,4CQS`9!F!&`OW0G*-IJZ'UD]C(G*/G5#VP!Z)0.CZX5NJFZUL@POC MG1G<.B0%\C@,=,<[R#5R0`JSTS;EEY:592KB7$15<;*I;$E]_A/Q!GB13$X& M_])EI%`)^ERTX)Q91$H\`5D4,\LK17V)<"^O)R534)JD@GF35U):;B/1*512 M24YN&H+`DJ.WNP?H!=ENF$NA&$9Q'3DHPKA\*@A_H>]V MDFUDJYB4TTC0-4E,26@-LL5U;E$I-"/;IED\0,GQ#!M64-^:8R=\GH4Z#XH7 M'F=E?9*MPDGV]JO@],O7+PC/GL$&[;_`&,[0YX!Z!4/[-#9.R^(9JK8BS[M9 MYG](^W(S'B#I]S3V#+!$X#;A6H,(7-[]K@E7'41PEWEDFW#?073=IOVA\N\V M?'OI.+BMPFQ.G"VG1Q/N;%1"6]GQV80K')4X4F;*BM[J:`QP+LSJ!B2Q3+64 M^,TUD9H0;L6#+L?L;T)\E0`T%5Z4U4&1^PWCV![^8XHA8ZF,QQ,XENNL/IZ` M,0Y1>CRA8P<]##Z>2#3F":_T:+3]+8/T(683,OWP`2N-J)&>[F=GJ)4=K=(3 MX7SCP90TP?2=[;Z2(0R(AT#6R`BFM/X;Q'OVDSM&H(*:.$R)G.P'3RZE],%S M7S!@OE[^"IKKT%DK!GW3QR]1$J*25S+KZ$I*B&&4QR44!Q;V`QIG'N7SM*X# M_[/K_X%\FO&%%7+(6UT.MJ-\0#27,A`*F&HM)@TU1P,4_14"QVA"!L95VCZQ M@+2R6G*0+&`[Q*%*2@]1-DX7F"C8-:0$\DZGL)^/IK=OYK/AS-`8-OV1DS^% M&)"$FM`AOEE/=^KEE/6S*0Q>6FB2ARB$ M`6U45093)D^N"*9L534P9=+A<@/*UE,#S>I-$)&AV:RC!HJU11#KTB66AT`# M:N"+GS=93:'<9TZXL7(U)NL"0O@^S1O%MO?:Z`ZM\`S)XO7E)"=,"*14`0OO#9_.D>5H*C+GA-N1CI;R?!2> M(Y';-^29F!1DE"RK)PG-"Z9G;C"C!FXP\:>!O7(LL(&PJTBYV!*?Z2*+)B4' MLZ;(2?'CIV)NY!W\-B'( M?-]\2!U%-B%5U+9!WIT82(]!J8L!5,T81P]7WS82L`0WK@ M^K=XV;[R.6S&7"[SH#8A!YLXW(%-TK-CZ:P>>[\O7GUIG*F[-'9"7RB/$O3J.OAV0E]H_"3HU?7N M<284$+K9M\9]KJYESYGK1N@&;8);77?=+KBW[D,G@-7URW'*.MX0F@2R)"-3 ME?014L92+-`I/:-YLQ>(9LX[9!X-H!.!@AY+'<->CS&Y#@C,;T(&B)@>7L0A M3#07"J$1`XA0IM&O3]#]M4U]`Q(BU2I0&5.1"5JKT-"QW!8_KIM;JX72:*INM]+2QJJ@W:DCU1SQS\!2;U($=!0>`\OW@VM@$0W,/DEQ+MAHE M!=_8,20(7V4ML;7$UA+[:"0V[Y:AI;124OK.P%[H$1M@0N7R%,1DL+X.V,8WG^.O>*;3M\)B?]"JJ6QWG9K<7XE;]/"S:B M9;:6V5IF:YE=H\P6W=:T%%=*BB=C-)IN)BL:(QN*6.&SCTDZH_5M*YGA9+N2 MG+^;[MJJ#C33@E\+?BWXOQG!O_,VK#4!I32!==(T;;WGOUO"Y@[+FUY010MH M+:"U@-8"^A!O>6L[7'WIFWV\6ZJ%S28F?[]CE]=6L1:Z6NAJH?O-"-V"K5-+ M7*4D[HT[G^,H*1)->N"&8??(H4'W>[6`=WC)78S"_&U1L!$ML+7`U@);"^QO M1F"+;K):BBLEQ>/$X7$^>;)**+^12'QG8&M*#6@EH+:BVH MCUY0[[+9:F&ME+!^C*;A&"WH&XO.[(A/FH],K'$,'$-V<-34@EH+:BVH&R^H MA38++9G9DOECEW8Q,0B"__D_4$L#!!0````(`*2&!3\%!0U%W!D``'-$`0`5 M`!P`86)M9"TR,#$Q,#8S,%]L86(N>&UL550)``,T6#Q.-%@\3G5X"P`!!"4. M```$.0$``-6=>7/C-I;`_Y^J^0Y8[U1-=Y5ER^T^TIUC2KX2[;A;7LL]2;9K M*P61D(0-12H`Y;;RZ1<`28FDB(.RC<>IFDP<^SW@/;P?#N+\[A\/BPC=$\9I M$G]_<'+4/T`D#I*0QK/O#SZ/>X/Q^7!X\(\?_OJ7[_ZCUT.7%S\.;M$HCFA, MT+#WD:2,/J!?`A(1AE."[O!#$B>+-;K&$Q)Q=$WCWR>8DT,D_S]$28Q^.;N] M1J^.3A":I^GRP_'QUZ]?CT@XPZR7J'2/@F1QC'J](L]_9=9]0&^/3EX=?5/Z MRVVRBL,/Z-7D-7D=X)/>VSYYW7O]?OJV]_YU^*KWYNVK5[C?/YT0?%K2.F<$ MIR)!%`J+A7;_Y*37_Z;7?W/7[W]X_?K#J_?_4Y9.EFM&9_,4O0A>"N'^FY[4 MJ)3$(1K&P1$:1!&ZE:(%X,%?_X(RX0\/G%84OIX6XB?'OWR\'@=SLL`]&O,4QT%%42;6I'KR_OW[ M8_773)K3#UREN#AP0\RP^]8$I%; M,D7*A@_I>DF^/^!TL8S(0?Z[.2/39BLBQHZE_G%,9B*`H9>>J7$MV*@>0A)7$H4\Y^*_4- M!94E+\M8)2J338)*@I$L[80UNJS2FF(^40D6)DORCDF4;ISH9?2>%,[GO_YM M$`2B;J3\!J_Q)"+G*\9(G!8Y*?^^/[`('V_LEN(5RQGAR8H%I%51R%1:6?!; M-)$*BTB(R^:(Q+W/XX,?"F&42Q^B7/Z[+(^G-5NTC9.$D^LGMWZ923<9/6!5 M4#`+BJS%CQ:K`>-^2@-![:=$GDKI! MWJ@"@'J3'39DV$;G$,6DD7??Z)@BT`20UNUV&.')(E1P]-^>]A4:\C7#DL2<\$$5!E/`5(W>B/3\3B?]>"]0C$GIBC,(D M6"U$^:@N^K%"53A+-<$,FS03@6`SF9$8JV.0DU MG"+,"(J3%-$XI/4 M2']EIE,:B]&,5%HFG"JQ"4F_$I+)!ADYXH],_>U%WIJBKS2=TQB=O$*+)$[G M7*:U)IB)4:TPFBGE9"D'JV*$BX)U$)&7RJ$XB7M%JIO4\%187DI,UH%-5KHLAQ3E1PJI8>V":(O,DFDTOQ?WQWML[L/T9(^OL&2[>LC MBP:H\Y;6EJRS]MP:>;_==K,1%L)*"ET8I^[E`P&L)<[0U`8;!D>!F%\M5I'\ MR%15\SQ9+!F9BV*E]V08!\F"7">.;C`-A_$Y7M(4:P'02/MDL-D$'6L; M:?$I3L,>%>._3`&4+W.A5S@RN`O#R_^M>"H'\/PN$=]YPEFJ/O.V3-\EYYC/ M;U@BO@U(>+;^S(DP?%2,QP=!*KX:9'L]F/"4X4`[)'B.K+R2^O3V:S'?9(48 M^6-%F6A;TT3.)62YRID$),:&7/Y6_AR(?-%*SM;+[[7MQQ+>9/D!MH8\'V;5 MZO5,,=J_;G(2',V2^^.0T*Q:BA_JM5'\ZK>!L#J4EE]%>%9#?:F9H-!W&J2A%.HG(@'.2F:;L=I\`I=6J;ZK)0U%I:JO,*";#?<*8RUB(!WH"= MK3B-"><7A`>,JL7+01R>84[Y:'HC8ELLUNK6EA^1D$>HVENG(>X33N72H1BK M%TFJ=4:5DORM2$LM!8ND(&GK=)/ M2?HK2>64NB,[LVVH; MOS*FK0H*!DX^%Q5'_NORCQ6]QY&<@ANDYYBQ-8UG_\+1BF@I<-'UBJ6#0;K^ M6L[#RO923OP0ESAZ,"F"6(N@83_8]W7LFT@WJ MW+>UUD&L)--1_BS[6Q]1/E"4)O$X%3;<8#9B8[FG/51C(M$^C^>8:8<=#IJ> M>;288X`PB1&7JH?B:YFA>ZD%C9]C5.K,N90!,&C*$#Y8I?.$T3^)=M;&H`$# M5MT,)Z"VXATA2E?\&I(:G>X$04/.5^[TY-*0Y&0F.%&3B7:*F&IQ&VDI.=H) M4D:K5!XVEY<$N,:JK`+)3,D.)W!*\IVBIR$$1H3J?@-S9)S$K8O!\&*C_LEVH%/JH5`/G?3[A_WL'\15)+[-&R/QQ]-O#M^\[1^^>_TN_YN<*/RO M54S0:?]074RAAO&G[P[?O7E[^.[D?4GLHZ!GCDY/,KEORZ#F*???'[Y[?VI- MN?_F\-W;-]J4.T*]?CZR*6(P=/-T-/TQ24(^3B)]/UJ5\LIV)6LMVEP=P%VR M)%P%*6+DGL2":O(@U\+4/G#M/DS@;\S&\J^RLEL"4*C(S]CBP*8A8!4QS["4 M\S;0DLTUF([2>I@ZWM?<0Z2V24&#VT1#G=P=_[J`KF6#E%8<$&7;-JD-(\6Y M5]"M4K8"-U'B^=A)ODWKBO(`1[\2S"[C\`*G]7&>4=33811=_I:M(L*5[K4XE,2!TZ@:]4`D-?9HL'G.HEGO92P!0K+ M[6=Q\=2Z"SC9HM($EK$88!!;,A)0G.];+I].U$94K^$5+*T9VB9IJZ$&^N49 M#5B@K#&HLF3V'`2CS6+\:"HO-A&#`V70+5$7GJ@O%#4C?2;O`[[!Z^R`O67? MQF-3]8GCXTPUW\Z7GZ8HIXORA)%*^1"IM'O9;I/4'A/QJGHB(?Q-&&+K"UJGA-JK^_[/LTV MQNDJ:JZ*>FCSHYIO5.F@4D+H2Y'4\U3)ID:JJF_YH*+54US0FPY0L3$@TBGOFHLD&&QR5 M7N=:/5`BU4#Z'=?BKX.B]=L?+3?%04#-TDVSG&<^*IG;P,B[$.@%&V,!UT'8 M==`?`724I\F82:WO>UR25BVZ0URJL`Q+.6I`)>"Z`)A MMCD]O3P@5=8;300]\N9/V:=D4VU=HL+FTZVZ^+5)PB=7+>S2H)8E(:=[29X(REY-43]S^6J*/-0,RM\>`:P@V;:4 MGG\,I.9V*.%W\HZ7A@%)]>^>1D&53'6XY#+HBY("^^II+,!B*+3KB*>(KL\% M0PQ'PS@D#_\D:UTA[\CYC'`]]$>!^BLE1 MR2\;[4\R%:!DAU7&V6&53!GZ7%.[L-0@>KZS3>V(ND@6F-87DG;^[)62+$\S M#U\R(=@>HE9XU0B7O/`5RRL:$78NQA^SA.E[AZJ4U\A6LC8'6(FB0A8VS(WE M6HWVKF>^@GY+9E2NW,7I)[S0CO;J8E[#7LW;'/>M+)+"L(%O+MMJY!N<@_@. MO<*4J;.#VUT6UAU)9AV/7YI&0W2W70H=I)301X*EBMHN`ODIZ12#\K>CW6\( ME'X4_9:<'QK%8_'9*N]]E>_GI.L;4?ZI_)I=+O3;=1V5/<+E9I%VZRY7LQ0A MYEE/9 M;5H7AB5*GQ9XK"`>W3*-Q2_H--MAYN>N&RVAN=1WJ3&X"HJ.TW4N';C&I=WU+3<=[D.=KF[IVI4M]9[(V2%X7F2_E<2:&,;O2/C#W:'X>SVONZ M->C0(VG.?-4JB8/CW:HNMR0@]'ZO&E-2[42EV=IC`XQM)(&FKY_?"?B*LDN6 M6UVIE4!GJ@M;D;!TZTZ;R-95H:M+S9[6W8S41Z4$.M73N#E7>$$,-\^"UB$- M;M8ZU.1^-^I0[5HTYYC6]4!K3\V8=E6G?AE?=^J-FUM=NH[/F2]SC6ERO!O5 M14X!QB*W-GU-60>TFI0,:5=%2HJ=&9NY.&.T&JY.-$!DK@]U7[M1%_)I]7B6 M/T!MGXMV30"TENBLTETDG1_>DP^*;U>$HVUGCS*#T8N5J$V@%X^W#Z$92V-) M=8/1&T:6F(9%AY)/E`WB<)3."L*"FZ56+[_ MH3/]P2-<+WPL/CN4DXER,K_#M0-[01_'MKDB.Y<=3*6N[D7Y1-++XN4:RRXT M)U6O%=9NCWWC4<;BH;SW`A9(][A4\7,L!!C8LI'6NLUJJ4'%*UQZ.RPCY#4J MW4;;A9ME'^$+^&C?#E"U-E@\!:T%HF[:(B1%("@7^=JH/D2?FIM(KPC;#>T* MLJ5H-R):>`**Y,^,IN0B^:J[P[Y!$`+/3>Z:V*N_]T(AD#VXEZMU@H.=(FZD MH>HA%!/9?KQL)X2YM:I+>J:BEKVA2<@DBPTI+_*ODI<=&/!IB[L.2).SSW\$ M_%I\,D;9.>3!`VVZ$+4NX>G@=RU;W?Y>*55*L=Y,_$`V` M?>47:('7OM2IWJ@L3Q/"[&I_(D-]-4&6M=;26W M!Z)9#8;>1EM<25'S:+RD_G=$5`+@K/MS"Z!F&+'35!=]@72Q#EE6FIS5.U2G M+*M,U\/!V?!Z>#>\'*/!IPLTOAN=__.GT?7%Y>WX[^CROS\/[W[M,GZFA:56 M10.,H_D9R@9!&,3,#SAF+5JQM-&E,<@3V@U`ON'U28V/W:#9O3FM*X#2;5N8 MW^4$=/7=7NYF8,";P8^8_4Y2N0=X3$0E=&@/31H>T3&8H7N#;IZP-'ND=+%1 M1GRC#*,/TU'#^N>K?K6'LUS=6I91MVN? M96"P1T*=K(V6@<15`Z"@(XG]`[@?J>`C#XVIV4K#(_J+I@3@"6VPRM:>RKVE M(:+QRTK+2HN$NMIS>/<4N(8:@'6HF;K2ZG:-W*\/,274R1IJO==D%]`N]B$. M`=R/U*[V(9L][/OV(4T)P!/:8)6M954-J[P)(RETN]IM^'`.N!X:L'2H?[H" MZG:]VZ^G,"74R7IHZ2E!VL:=P".!^I':AI]C>`:#7,-V9HC(#0F\:;/RLS)C^?HBE\K[Y-2G1$Z'DKR*+_#[46N M\A((XZ=TX1"IM4M0W&T<5=`W.M^I:F`;-5CUNE`M;&,"=19QLQ.XV!H,.RQP M#8@35X_H]/%D$2IJ^F]/^XH9^1N154KX79)/9^)H66BU6?I1K`N?/],%VC)@Q2Q`$@.-D9_>9E_-O@&+[;W93.@_OFJ6JV(+-70/K,)9R336.G,)@50]EM\GI8[TW&`V8NK[ M-E2/_-X0-IYCIAL_.2K[K').%ND.(T18?,>=H4TB2*5RB):8H7N9`"B*K2)5 MP="]4.`15+;PP2H5W3#]4]_XF)7`D*M;TA:UK69W6-.%1,]88RETA:TAYZM6 M7.4*P$QE5K3E*=/J&DO5$-@X*GG>%89&JY2G8I0BOE5;A+"L!4Q3R92V2"5; MU:YQU1`6&USU@H`G3/7*3J',),%(4MFWI>=O1_V3[8"JU-^A'CHY[/?[\A_Q M$2YC\VW>?&5WO6X#)43C).[0:*P2,CUQVP(#HDQ>(-MX<:SYB*B+IE\*;>;\ M.U\BW").-=2<2N5)%N[%AVQ`2*A>7RV^][,;^-BISE>(E$7!`7B:G9QDURV6TU1WX7^I_M$Z':_-?TOCVH$KNX1%GE[GUP/VC7>UX]BG/,'QEA5MM%1[+2X?"`LH-WS4 MV_2@\&TRQAE7DFLH2F5**%F"[SUQCI$606V9`"'7/&.OO\?6J.(7-*T=>L8: M%F#`=Q2X!*&&D]ES()*REZS%J.$B64W2Z2HJ7N[41U"OXIU.2AZI;(TTY5SEI\A,0"PL-$!#H8E_\&>8`@J-Q'3BW6(]L`W_PV%D.(>Z(`6!H M.5V5BX$>*=259E/(P<]'R>DLGELCGZWC^J_V1E&/"#3EK_]*#U4WEM.*3DJ>\7/Q2(M M@4KY$,TR=84BKB0`2U^;4%4!="X5$`;EEIHSS$EXGBRD*4WKWQ9AGXPU6J"] M"EP(]R92&I7%H=Z5;&>\7/#(C0\LQGNK!498*M3K706AG,YB.J6!G/C/IFQ% ME;Q)(AI0PJV]O)NRSUK@9)$.K*TRVFJC0AV4KU9AJO#F7B(@_!670US3F`S% MC[K9C@9!GUSMY*YMG')!]$6*(B4+UQ` MVUXW5&AW#SAKK#3@F0L&%,`[N3',%MI,"`(JE;.]8U-BW:"D4J"-/&Q]@HF\ MXU.IL(^CMGPWM#O/GSZ3X?XX=GG2M$./F+9^MK0;#Y6V?IITW``*Z#)2N]=' M._C>Z'BU7$:J1<91,30OMV_>V!F)U-=+Y7) MH$P(@@5M\PSR6R0D?OG_SV@")N_U[7VCE MP0L0U+6GTS4./\D)X9\)GBM+`I720%_GA!&D\E$KZ'EF2`CF9QD7V5E&IC9$ MR+]PA!$7NA%!PHO&5?9G:26>J9AP7DQ9;8.^EN21T&_.&>]93AGUN>/7(D7Q MW^*_Q`]R85G\Q_\#4$L#!!0````(`*2&!3_`E2I(;A(``.E7`0`5`!P`86)M M9"TR,#$Q,#8S,%]P&UL550)``,T6#Q.-%@\3G5X"P`!!"4.```$.0$` M`.U=WW/CMA%^[TS^!U5Y:6#9R('>]'/[U\=.__%J,&C__--W?_OT]TZG=7/]2W_4&GHN]$!KT+D'/H9O MK=]MX`)L^:#U9+TA#\V6K0<,"/!\RZ?CMNZ@]^?8(N"'%OM_IT5_]?OEZ*[5 M.SIIM9Y]?W[1[;Z^OAX!9VKA#@I&/[+1K-OJ=%9/_BV4\:+U\>BD=_3CQE]& M:.$Y%ZW>^`RSSH^/AT#ZW2CUQ4&H7`. ME9OV/CXYZ1S_V#G^\'1\?'%V=M$[_\]F:S1?8CA]]EO_L/])&Q]_Z+`>"7W\ MT!IX]E&K[[JM$6M*6B.J`_P"G*-H)#?20XLJW2.?VQO0W\;8/4)XVJ5CGW97 M#=O?_:T5-KYX(S#1X?5TU?RD^_O]W:/]#&96!WK$MSP[T9$-EM7UY/S\O!O\ M-6Q-X`4)1KE#=J`:`0%;W!;LOSJK9AWVJ\Y)KW-ZO7X_ZEX/A_D@(#Q8&TB]" M8FC_&?C0MMS]@Z*?,IJ!ONL#[-%7_P)V0)$>:^_B7EGD^=9%KV3@.1`#V]]! MW/18^Q'W"_(!>4+K=[I^)+E<$+I^$G(-B(WAG+WHON=<6@22X633DCR!-__2 M1?:?LO#V^NRJU?$(IQZ=X[;E^7W;IM;-I];X`;G0AK3'_E4@^+RJ8=]:$/]F MN0MP#8GM(K+`E:#-?TS5(`?>"_V!\#)^>@48H>O2SVC`S.@4 MCEW0)P3XI%+0DL^M6@WQ,^F2BF9SX)%@'1D!ES9QKA"A7]XSM6*7C!,_6,N@ M5P5ZV560ZC\)9A[ISJ'B3R+G*55#O+&P1]=4\@!PH.D*\/$?434X.J=FT`_^ M23^]*Q28#[J)I,:CTC*]9& MN<=73F7`E/T<@3G"[/54J@*1AT6`YQO$CGDG$LAI8^`Y;`,6_I8]=I^;R$`$ M*@05*/%N`V"7O07VCT[HN3B)MM;?TU]]Z]-' M.^SQMZXU70WG6F/@?FZG_]ZM7)ZK!6:;M5OZ/BSW#V#A&\^YIF\M0S1N4SDI MTQ.5_>:;R.OICXF/+;:#2@@GW[]ZO:[$"+5%5WZ(G%OZ.Y*A6'[;0\O)WJJ8 ME''+P\FX\2;IP@`&=&W)$S2S^>&D#=\C_W/*;G405@RQU04_/V;[#DR95J=S#Y*+]"WJ-/S6;`*,EPX3/O M,CL;X`N;U^E0DE^CF04]KHS1GP\ES2UT`;ZBW]V4;LBY0B5;'4JV$9A"9JX\ M_XLUXWX:V\VJE^X.3"TW?';_#68MP-LMJI?I"5ML%C\N9V/D9DB4_/M:GDVJ MV<=)V2QLKP:B_TSPS/2)2M2B.P\\WQW[&;IKBCK!:%:&HZRD05D+80MA!^#@ M5)#^K]V:4QN"Z4"?V[UV:T&HK"CPEUIJT(I:[16XI$V*L9TT`-L6XX_!]1H` MCD-V8I"G#0*9XL@QS+/&P4QL66*@'QH`=,M:Q.`^-@!<-GF(,?ZK,1A3)#T& M^6,#0/(],S'.\P;@S&3B:X@G3:`W(INV&+&NI"=SJ[Z"F-H5Z$]0<_'DO]X5 MN.-C?>%Q]FG).;G:CLN^K4_=;3=]M91M&IO[4$+&I??(.\N]PC8`+XP:;X`7TSZS"Z* M,+"#M8V#M$(`G/:*I%_,%L%!?W`>R`(`,'@&'H$O(#P3OT.$4!T/)T_6&Q^3 MU"A*D#H.#)>/!PLZ`^_*FD/?VG;4%+56(GD0H$3-/RC.KDXYV&<1NKD+/@J M$VV42RFDU.VV*J1FP:`LNH+^N/G?@B[(;A!LX%]9&"\IIPPBZ3@HQ/HJ0<4/ M'>%AR>FA"D'$\W-?P78S%;)>@PF@,]D9@1?@+0K8"Z>Q2KFI1=NPYE^09PLA MX'9KRC%8>PO_"7SF/G@$U.X**#ZOAPH$V^&[A;PCIX,*^1]PQ(,* M26I62T42SRVX"J%>15"+["Y%>JI!A.8`^\L'E^5V>0Y;".=L$\/G`;E=5&`8 MT8\2>L!9)3AL^*(HTX8VY"$1Z*@"S]K+G#K)V9(_HZ%2>3.\X@4V0:BK4DQ9 M$:&<1FKD%.1SFC`X:5[:MDI7('W<7TDU],Q M4$P<7KZABU'J&"DFCE+,-1&CU3%@3!QM%B(=(\-D/$-/%$P6,1_[\)%ABM+ M((B/?,L-6FJN"(P(:,AW+K2SCO6E8W":_,SGH>LU:LVO/`I,S6N6]45O MOOD\WZG>F1G[0%]\:JIWXL8^=)#GN]4[GV//\S\CJZ,AZ]X^%)4;AJ)WQL@^ MX.>UUCN79,]?">?D-I5JTMQ/1V(GL1T#G4I4:1S-EM83+UXYE?#RSE7%"TQ+ MI*C^G2F[P,LW6B,[45PR9NW&+4.E-:F8/,)$U)'A;68P.; M?<19TTRZ8E!Y4UOW1#KQT],MGUHZOB;^$G4^*9'?)25#W6.4.F^-Y%!RTY=B ML#KOA.3`BL3TQ+AU/@B1PYT57Q#CS-N_!/(MU@$,(8T*@A*Z'EW+?9;PV@@5 M22=?+"![4I5U26(0[$=H*O>%5TF1,M)-)3 M<1)96"RBO_"?Z=SX*WZ-?"2I'EH@&!"R$)<^:JV%Y/SJBD)=FI)4UJP$HB1) MEUPV!#NKQR6X>!1TT@5'[A*2TT$7^8L7DJ)>)BS>A,7K'!:?V$:%TYRJ!&L1VQ,&=BR'-)$-ZES8U)[+F1%;R1%:A3SI] M?:^*ZG$S=J?97P%.)E(R$9"S^RGHI,;M2:A*66H?>40NWU&;;*5*4A;XLKI1 M+T?41#,=9"UP0'";JY!]^^)*=O6R386[AN["Y_KABGHUQ1V^0XTU^F!V4CKT M'BT7#"T!YKL-RUX@/>%Z?LJ.IJ7:V.B6^I;8J M#*M?T,DRG`,9/54EGE M.-DI5-!)3>4O`NA.E%6(N`8OP$5!19=\&/E]U*`(DDN8"?^%W97$FSWI=@JE M+1!2K6P%RTBJF9*C5,J2221)L(_EF^O,IDID!J[+*@E1DH,MEWY!?6<&O>"* M+^;VR/_P!#N;T`(=CN$YUZ-_!7#Z3'?/_1?Z#J?@RV(V!CC864?;ZJ(`D[*C MJ/1@%OE.DJ<*6]ZK>F0^R4`L,+KU2#"1`2RZZM4CZ40&>9%/N1Z9)[+?;]*G MF\HR:5@::X&GIKZG:@V-J!+>.V_7'4NYAE)Y1B4#.MTPH'9<10RQ\]]% M9`V?T`C8R+-A4(\_7BN?$)/T`:,72#%?+G\E@!K1-6'KVSY\"2O"%5Q@7<6C ME$36AF68`F/I0'_!TF7"6L[.Y<+_@OP_@,\*-O$B;46[J\'6R+N]JT;UK:<1 M+FK,(>.Y-LL"`M<@_"D%CS.$"HRK@JQR49I%O=0@H5;%AJ$9]9S-HS8N"GX/ M)7'YDPFU4\/)S9O];'E3,*+&;.AE3R$.)*DA3,3^]K%&XE*S]8UF'%T+=M8! MU[O*1$@LJ@-OJXHY!V-Q/[W0Q+<[20/:Z*H-IJWZZ3*8MKOJ@6FKT+DPH.U^ M>J!97;,E\VHV^^B!8KW3B?8(Q4DTH@/H@2^Z\VLUA3+O_A+&*C28JJR;[F`7OB6R?'\U)51C M`9E45(7WEL_FR'(XD9ESTN,H1\MT/@S.R,C-&\`V)#EU;XOZ*4+S`@F5@\ZH M:[08^Y.%NW(L$'PNRC)]HK.XH'#KCJ@VYH$S&GLZN,6:CR+#UY16'..5(]4CP.I:I\ M8U"/U(]#Z8IG=':Z9*86-U\>2L-9CL%4-LJ[UI#H<6>LM=-F7I!U.%M2$%T1 M:UKG;'95\[-$EF'>E?=FP@JLH>*'9K'2=4Z0D3\&S-='U@&\V+7Q-9Y^^U9B MXCQ9+$O$:$_RG%?LZGFC5GZ@4/,OI:]`A:E(GIVNK7^76DS%#J4R91JCPJ;6 M%"D=?[#E7BDZ.:A'-:S]J$,F:"55-*MA^8?E`R(2$TSLP#=5VZ%I3&)/VI0_ MUJS'75V[J:?$F78]"DQ4]`WFA">D2E*8#U'"4&1&PS6]"$;Y2"NA['Z=/3_[ M@5Z-YZT>A1[W-GF$@QF;7AQ2N)A&^1G5TWE&[80_UPS$^.M?I*?,?BG&KW-D M@F#=%*E$V#7R4YU=`H+ER*12SF/D[[G*CF#Y@5A9)?R0\^`-4'FP_VY4]JVW MJ;02GL=0:3>>TP25"0?8Q2K3>4\O$IM9WU+5^=&;IGB3SNCD`EF3JYIHY2#9 M4KR'KF-%905T6[F^HGG]0LGE@M!W2L@U(#:&\RA(E55:(RR>*Q;GB3[^TF7N M-`71R"6DC*38"DPN,5!3JIKHDG',R5+B3U%.K+EH+Y-947%6@CG>+0M']P&YT(:TQ^Y$R1"' M=TL8CF$ZANF49#H%JZ8A.!J":BK!6==_B.>B MX3?ILKE9VLFV(KE=#+LQ[,:P&\-NFLQN\M?,%+EI3%:N(4:-(D;L"O)7Z+K! MQ:V^Y4TA!1Z6B3!4*>OV'#E]91LIR4$,G3)TRM`I0Z>:3*=DUU7C/=(05%-) M4CP#AY/-"JTCX+*4^2M$?!+7<%UG[:N,LMY5Y&QSL.NH)O[:\"K#JPRO,KSJ M4+QJ9SM@/%F&I-6"I*WK:!N_5?:-H'SM$[X]";LFH_`5M7ZEOB"Y.]8//;&W^0X32&TQA.8SC-P90D`8)/)8$N5?_3?EU6U+"['5=-+0+H?_P?4$L#!!0` M```(`*2&!3_24P*T,P<``+DP```1`!P`86)M9"TR,#$Q,#8S,"YX[T^Y5?/OWXP]6_/(_T MNI_;(S(4G`D@?>\.C&(K\B4`#HH:(!.ZDD(N7LDX>((%_4"F5$-(I"!?;D8# MTJC6"7DR9MGR_9>7ERJ$BJ@5SXQ/.2KGY?.]4B%]5ZH_HQU3*2D0A; MI#%M0C.@=>^B!DVO>3F[\"Z;8<,[OV@T:*UV-@5ZED)U%%"#A"1$1Q%=J]>] MVD>O=CZIU5K-9JMQ^9^TM5R^*C9_,N2GX&]:4]:1]N:4+C?V,ZJG MSCIN\-<9K7MG]5V4>5V"SH2YEFP;Q\;':OND/[WK=:F=XYQ"UB[-: MREY((:)%=ORA4;[MRD,,R\]K$+M7`= M5PC#D5;(JQ./)/#T)5*1-1=)D5WY^PS[Y!'.G$/QR5T' ME`<1=\`!WL?@V"(/N%0X)0ES!'+KV=NX^&FBSO<1;8S>NL$UG-TR@;,=X;WX^&@WVU/>EURTQZT[SL],OZU MUYN,3]*]3[H'JM#D"0S#W)36T:&_(6:SN)CDIQUW?CZ)6T![1\F&MV3XT!NU)WTT.`E60+`.U4^W7+[HO@B9 M@L!D"W9HEB_817'!.NWQK^1V,'P\"?:F8/?2@)[(S>2W2:V^B30>.+3N@@X4 M6UK?VB*\H9KIX>PA%>D$5N:&R^"/E,#?E39_0/S;;GR8#KC4D0*\N:?&7L@9 M2?IR^R'7A7V*G2RI.NV(CAP78S87N"H&5)AVX$X2>'!_D)P%#!&EQD)!JGS] M/^[KGV(E6UJ2$XT+Z_Y+67J=\HCV":ZI-3Y#/D*7^XK;,F(8R-W0.U#U\=) MV?+*]O%\+HQ4K]L$EQ,VER!7UWIM7]>$Z_26'J7E9RG#%\8YKJ=]^SEASJ8< MVEJ#T<>J6Y(R7^_ZH=X))5ESNH4ZZ?,T!,H/@6UZ<68Z+I+L[#8]C9GM[.I[0U?&S M?0Y!OK!GAV^_Y;*_WYRF^V/$[%$E<&.K'T"YUZVXUG:D.[.`L`>68]_5DI3YLI_ORYYB=ZOV#O]I!)0? M`7A451&$O95=X@X]J,67RRR*HI6(:R",+(67X_Z"Z_6.K&D8P(ZY@ MH65_L+^N:+986(9_2+3[KWF!H!&2$73Z=X6LV*_\=`T(WNW6B%QA MZ#B3$G%0L))3)D76E5@#&3BB'(B]\Q*<9Q]Y]89W5J^N=!B[6,:#;:;+>9#@ MRGJ068E4M.\$8#L]+]1=;C776]VZ+C/+QWS@1F^XO"U7^>P?%&\52L(^RF;B MTJ:_?O$>%U)U9R7=D.+^.$_RRO/>(8Q]4E:7;Y6[Y;J3A4MNWN7(7@5=(2<2 MC+UX5^>'E7B%^D_!XNLWO(C+\YP;UY5WG&;LA/[U2/QZJ5I79K9,\KR/^V*[ MDZL0.M5&TW4JRG*P=+P+*+*2A;7A%T&8^PP7T%U,/(V"V- MK>M/I>,8\,X@<,U_V1M]Y:\G2;S\'U!+`0(>`Q0````(`*2&!3_AJ'T%#3X` M`*6M`@`1`!@```````$```"D@0````!A8FUD+3(P,3$P-C,P+GAM;%54!0`# M-%@\3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*2&!3_31VMV_PH``*2, M```5`!@```````$```"D@5@^``!A8FUD+3(P,3$P-C,P7V-A;"YX;6Q55`4` M`S18/$YU>`L``00E#@``!#D!``!02P$"'@,4````"`"DA@4_JCYA9@P2``#? M.@$`%0`8```````!````I(&F20``86)M9"TR,#$Q,#8S,%]D968N>&UL550% M``,T6#Q.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`I(8%/P4%#47<&0`` M`Q0````(`*2&!3_`E2I(;A(` M`.E7`0`5`!@```````$```"D@2QV``!A8FUD+3(P,3$P-C,P7W!R92YX;6Q5 M5`4``S18/$YU>`L``00E#@``!#D!``!02P$"'@,4````"`"DA@4_TE,"M#,' M``"Y,```$0`8```````!````I('IB```86)M9"TR,#$Q,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``9Y`````` ` end XML 27 R11.htm IDEA: XBRL DOCUMENT v2.3.0.11

Stock-Based Compensation
3 Months Ended

Jun. 30, 2011

Stock-Based Compensation

Note 6. Stock-Based Compensation

Total stock-based compensation recognized in the Company’s condensed consolidated statements of operations for the three months ended June 30, 2011 and 2010 was as follows:

 Three Months Ended
June 30,

 2011 2010

 (in $000’s)

Cost of product revenue
 $ 76 $ 62

Research and development
 500 310

Selling, general and administrative
 1,756 999





 $ 2,332 $ 1,371





The $2.3 million in stock-based compensation expense for the three months ended June 30, 2011 includes $0.9 million related to stock options and $1.4 million related to restricted stock, restricted stock units and the Company’s Employee Stock Purchase Plan, or ESPP. Stock compensation related to restricted stock and restricted stock units is primarily related to performance share awards, as described in more detail below. The $1.4 million in stock-based compensation expense for the three months ended June 30, 2010 includes $1.0 million related to stock options and $0.4 million related to restricted stock and the Company’s ESPP.

The remaining unrecognized stock-based compensation expense for unvested stock option awards at June 30, 2011 was approximately $5.6 million, net of forfeitures, and the weighted-average time over which this cost will be recognized is 2.4 years.

Stock Option Activity

The following table summarizes the stock option activity for the three months ended June 30, 2011:

 Weighted

 Weighted Average Aggregate

 Average Remaining Intrinsic

 Options Exercise Contractual Value

 (in thousands) Price Term (years) (in thousands)

Outstanding at April 1, 2011
 5,945 $ 10.27 6.30

Granted
 39 16.83

Exercised
 (799 ) 9.51

Cancelled
 (109 ) 11.59

Expired
 (52 ) 23.51







Outstanding at June 30, 2011
 5,024 $ 11.85 6.46 $ 31,443







Exercisable at June 30, 2011
 3,565 $ 10.64 5.67 $ 20,140







The total intrinsic value of options exercised was $5.8 million for the three months ended June 30, 2011. The total fair value of options vested during the three months ended June 30, 2011 was $10.0 million.

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The fair value of options granted during the three months ended June 30, 2011 were calculated using the following weighted-average assumptions:

 Three Months Ended
June 30,

 2011

Risk-free interest rate
 1.83%

Expected option life (years)
 5.30

Expected volatility
 51.6%

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock. The Company estimates the expected term based on historical experience. The expected dividend yield was zero, since the Company does not pay cash dividends and does not expect to pay cash dividends in the future. The calculation of the fair value of the options is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historic forfeitures may not be indicative of forfeitures in the future.

The weighted-average grant-date fair value for options granted during the three months ended June 30, 2011 was $8.39.

Restricted Stock and Restricted Stock Units

In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity as follows:

 Three Months Ended

 June 30, 2011

 Number of
Shares (in 000’s) Weighted Average
Grant Date
Fair Value

Restricted stock awards and restricted stock units at April 1, 2011
 407 $ 9.84

Granted
 564 18.49

Vested
 (134 ) 10.88

Forfeited
 — —



Restricted stock awards and restricted stock units at June 30, 2011
 837 $ 15.51



The remaining unrecognized compensation expense for restricted stock awards and restricted stock units, including performance based awards, at June 30, 2011 was approximately $10.1 million and the weighted-average time over which this cost will be recognized is 2.7 years.

Performance Based Awards

Included in the restricted stock activity discussed above are certain awards granted in fiscal 2011 and 2012 that contain performance based vesting.

During the three months ended June 30, 2010, 311,000 shares of restricted stock and a performance award for the potential issuance of 45,000 shares of common stock were issued to certain executive officers and members of senior management of the Company, all of which could vest upon achievement of prescribed performance milestones. During the year ended March 31, 2011, the Company determined that it met the prescribed performance targets.

During the three months ended June 30, 2011, the Company determined that it should have been using the graded vesting method instead of the straight-line method to expense stock-based compensation for the performance based awards issued in June 2010. This resulted in additional stock based compensation expense of approximately $0.6 million being recorded during the three months ended June 30, 2011 that should have been recorded during the year ended March 31, 2011. The Company believes that the amount is not material to its March 31, 2011 consolidated financial statements and has therefore recorded the adjustment in the current quarter.

During the three months ended June 30, 2011, performance awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management, all of which could vest upon achievement of prescribed revenue performance milestones. As of June 30, 2011, the Company believes it is probable that it will meet the prescribed performance targets for these awards.

As of June 30, 2011, the Company has recorded $2.2 million in stock-based compensation for shares and options in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these shares and options at June 30, 2011 is $5.8 million based on the Company’s current assessment of probability of achieving the performance milestones.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R5.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands
3 Months Ended

Jun. 30, 2011

Jun. 30, 2010

Operating activities:

Net loss $ (4,594) $ (5,980)

Adjustments required to reconcile net loss to net cash used for operating activities:

Depreciation and amortization 1,046 959

Bad debt expense 15 53

Stock-based compensation 2,332 1,371

Write-down of inventory 156 623

Loss on disposal of fixed assets 5

Deferred tax provision 96 243

Gain on sale of WorldHeart common stock (239)

Changes in assets and liabilities source (use):

Accounts receivable 847 767

Inventories (1,601) 645

Prepaid expenses and other current assets 220 292

Accounts payable (1,360) 705

Accrued expenses (5,443) (2,169)

Deferred revenue (270) 78

Net cash used for operating activities (8,556) (2,647)

Investing activities:

Purchases of short-term marketable securities (5,001) (1,501)

Proceeds from the sale and maturity of short-term marketable securities 4,500 4,000

Proceeds from the sale of WorldHeart common stock 239

Expenditures for property and equipment (472) (289)

Net cash (used in) provided by investing activities (973) 2,449

Financing activities:

Proceeds from the exercise of stock options 7,629 94

Net cash provided by financing activities 7,629 94

Effect of exchange rate changes on cash 220 (743)

Net decrease in cash and cash equivalents (1,680) (847)

Cash and cash equivalents at beginning of period 5,831 4,788

Cash and cash equivalents at end of period 4,151 3,941

Supplemental disclosure:

Fixed asset additions included in accounts payable $ 44 $ 31

X

- Definition

Proceeds from (payments for) the sale of subsidiary stock.

+ Details

Name: abmd_ProceedsFromPaymentsForSaleOfSubsidiaryStock

Namespace Prefix: abmd

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Future cash outflow to pay for purchases of fixed assets that have occurred.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Gain (loss) on entity's disposition of equity in securities of subsidiaries or 50 percent or less owned persons. Reflects the difference in the parent company's carrying amount of the equity interest in the subsidiary (or equity method investee) immediately before and after all stock transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 9
-Section 04
-Paragraph 13
-Subparagraph g

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.13(g))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4542-108314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Section 7
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Concepts (CON)
-Number 6
-Paragraph 86
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 16
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.5)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R7.htm IDEA: XBRL DOCUMENT v2.3.0.11

Significant Accounting Policies
3 Months Ended

Jun. 30, 2011

Significant Accounting Policies

Note 2. Significant Accounting Policies

Goodwill

The Company assesses the realizability of goodwill annually, at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. These events or circumstances generally include operating losses or a significant decline in earnings associated with the acquired business or asset. The Company’s ability to realize the value of the goodwill will depend on the future cash flows of the business. If the Company is not able to realize the value of goodwill, the Company may be required to incur material charges relating to the impairment of those assets. The Company completed its annual review of goodwill as of October 31, 2010 and determined that no write-down for impairment was necessary.

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed (generally upon shipment) or services have been rendered, the selling price is fixed or determinable and collectibility is reasonably assured. Revenue from product sales to new customers is recognized when all elements of the sale have been delivered. All costs related to product shipment are recognized at time of shipment. The Company does not provide for rights of return to customers on product sales and therefore does not record a provision for returns.

Maintenance and service support contract revenues are included in product sales and are recognized ratably over the term of the service contract. Revenue is recognized as earned in limited instances in which the Company rents its console medical devices on a month-to-month basis or for a longer specified period of time to customers.

Government-sponsored research and development contracts and grants generally provide for payment on a cost-plus-fixed-fee basis. Revenues from these contracts and grants are recognized as work is performed, provided the government has appropriated sufficient funds for the work. Under contracts in which the Company spends significantly more on the development project during the term of the contract than the total contract amount, the Company prospectively recognizes revenue on such contracts ratably over the term of the contract as related research and development costs are incurred.

Share-Based Compensation

All share-based expense, including grants of employee stock options, restricted stock awards and restricted stock units, are based on the grant-date fair value of the awards, adjusted for expected forfeitures. The fair value of stock option grants is estimated using the Black-Scholes option pricing model. Use of the valuation model requires management to make certain assumptions with respect to selected model inputs. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on historical volatility of the Company’s stock. The calculation of the fair value of the options is net of estimated forfeitures. The expected term of options represents the period of time that options granted are expected to be outstanding.

Management estimates the average expected life based on historical experience of the Company’s option exercises. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historical forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model because the Company does not pay dividends and does not expect to pay any cash dividends in the foreseeable future.

The estimated fair value of all awards is recognized as compensation expense over the service period. Accruals of compensation cost for an award with a performance condition is based on the probable outcome of the performance conditions. The cumulative effects of changes in the probability outcomes are recorded in the period in which the changes occur.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies, which are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that any recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R16.htm IDEA: XBRL DOCUMENT v2.3.0.11

Segment and Enterprise Wide Disclosures
3 Months Ended

Jun. 30, 2011

Segment and Enterprise Wide Disclosures

Note 11. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 61% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2011 and March 31, 2011, respectively. Remaining assets are located in Europe, primarily related to the Company’s Impella production facility, and include goodwill and intangibles of $41.0 million and $40.5 million at June 30, 2011 and March 31, 2011, respectively. Total assets in Europe excluding goodwill and intangibles amounted to 8%, respectively, of total consolidated assets at each of June 30, 2011 and March 31, 2011. For each of the three months ended June 30, 2011 and 2010, international sales accounted for 7% of total product revenue.

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R2.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands

Jun. 30, 2011

Mar. 31, 2011

Current assets:

Cash and cash equivalents $ 4,151 $ 5,831

Short-term marketable securities 54,982 54,481

Accounts receivable, net 14,541 15,376

Inventories 8,879 7,505

Prepaid expenses and other current assets 1,339 1,544

Total current assets 83,892 84,737

Property and equipment, net 6,214 6,273

Intangible assets, net 1,279 1,632

Goodwill 39,752 38,946

Total assets 131,137 131,588

Current liabilities:

Accounts payable 4,964 6,283

Accrued expenses 8,700 14,078

Deferred revenue 1,715 1,982

Total current liabilities 15,379 22,343

Long-term deferred tax liability 4,106 4,010

Other long-term liabilities 469 492

Total liabilities 19,954 26,845

Commitments and contingencies (Note 9)

Stockholders' equity:

Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none

Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 38,560,747 shares at June 30, 2011 and 37,756,719 shares at March 31, 2011; Outstanding - 38,509,793 shares at June 30, 2011 and 37,705,765 shares at March 31, 2011 385 377

Additional paid-in-capital 389,217 379,218

Accumulated deficit (279,364) (274,770)

Treasury stock at cost - 50,954 shares (827) (827)

Accumulated other comprehensive income 1,772 745

Total stockholders' equity 111,183 104,743

Total liabilities and stockholders' equity $ 131,137 $ 131,588

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19
-Subparagraph a
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Topic 210
-SubTopic 10
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
-Section S99
-Name Accounting Standards Codification
-Publisher FASB
-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Concepts (CON)
-Number 6
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 18
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.18)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Section 45
-SubTopic 10
-Topic 210
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765
-Publisher FASB
-Name Accounting Standards Codification
-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 9
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 17
-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 19

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 25
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 32
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.32)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 21
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 02
-Paragraph 29

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 8
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 4
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Section 45
-SubTopic 10
-Topic 210
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765
-Publisher FASB
-Name Accounting Standards Codification
-Paragraph 1

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 12
-Paragraph 5
-Subparagraph b, c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Technical Bulletin (FTB)
-Number 85-6
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 7 98 1 false 0 0 false 3 true false R1.htm 101 - Document - Document and Entity Information Sheet http://WWW.ABIOMED.COM/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information false false R2.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://WWW.ABIOMED.COM/taxonomy/role/StatementOfFinancialPositionClassified CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://WWW.ABIOMED.COM/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://WWW.ABIOMED.COM/taxonomy/role/StatementOfIncomeAlternative CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://WWW.ABIOMED.COM/taxonomy/role/StatementOfCashFlowsIndirect CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 107 - Disclosure - Nature of Business and Basis of Preparation Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock Nature of Business and Basis of Preparation false false R7.htm 108 - Disclosure - Significant Accounting Policies Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies false false R8.htm 109 - Disclosure - Fair Value Measurements Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R9.htm 110 - Disclosure - Inventories Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories false false R10.htm 111 - Disclosure - Intangible Assets and Goodwill Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Intangible Assets and Goodwill false false R11.htm 112 - Disclosure - Stock-Based Compensation Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R12.htm 113 - Disclosure - Income Taxes Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R13.htm 114 - Disclosure - Net Loss Per Share Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Share false false R14.htm 115 - Disclosure - Commitments and Contingencies Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R15.htm 116 - Disclosure - Accrued Expenses Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherLiabilitiesDisclosureTextBlock Accrued Expenses false false R16.htm 117 - Disclosure - Segment and Enterprise Wide Disclosures Sheet http://WWW.ABIOMED.COM/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment and Enterprise Wide Disclosures false false All Reports Book All Reports Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Mar. 31, 2010' Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS abmd-20110630.xml abmd-20110630.xsd abmd-20110630_cal.xml abmd-20110630_def.xml abmd-20110630_lab.xml abmd-20110630_pre.xml true true EXCEL 33 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E-#-B,&5E85\S-S`T7S1D,S%?83,Y,%\U96(Q M-6-B-C,T,68B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S7V%N9%]';V]D=VEL M;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I M=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^2G5N(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,3QS M<&%N/CPO'0^43$\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7V4T,V(P965A7S,W,#1?-&0S,5]A,SDP7S5E M8C$U8V(V,S0Q9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-#-B M,&5E85\S-S`T7S1D,S%?83,Y,%\U96(Q-6-B-C,T,68O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!L M:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA3H\+W-T'0^)FYB'0^)FYB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E-#-B,&5E85\S-S`T7S1D,S%?83,Y,%\U96(Q-6-B M-C,T,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930S8C!E96%? M,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R MF%T:6]N(&]F(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS.#4\'!E M;G-E*2!I;F-O;64@.CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'!E;G-E2!O9B!S:&]R="UT97)M(&UA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;F1I='5R97,@9F]R('!R;W!E2!F:6YA M;F-I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA#L@34%21TE.+4)/5%1/ M33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#$N($YA='5R92!O9@T*0G5S:6YE M2`M+3X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P M>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O M;G0@6YA;6EC('-U<'!O2!P6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H90T*86-C;VUP86YY:6YG('5N875D:71E9"!C;VYS M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N#0IP2P@ M=&AE>2!D;PT*;F]T(&EN8VQU9&4@86QL(&]F('1H92!I;F9O0T*1T%!4"!F;W(@8V]M M<&QE=&4@9FEN86YC:6%L('-T871E;65N=',N(%1H97-E('-T871E;65N=',@ M&-H86YG92!#;VUM:7-S:6]N+"!O<@T* M4T5#+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X M.R!415A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P>"<^#0H\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY);B!T:&4@;W!I;FEO;@T*;V8@;6%N86=E;65N="P@=&AE(&%C8V]M M<&%N>6EN9R!U;F%U9&ET960@8V]N2!N;W0@8F4@:6YD:6-A=&EV M92!O9B!R97-U;'1S(&9O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@,BX@4VEG;FEF:6-A;G0-"D%C8V]U;G1I M;F<@4&]L:6-I97,\+V(^/"]F;VYT/CPO<#X-"CPA+2T@>&)R;"QB;V1Y("TM M/@T*/'`@6QE/3-$)TU!4D=)3BU4 M3U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G M/@T*/&9O;G0@$$P M.S,Q+"!A2!N;W0@8F4-"G)E8V]V97)A8FQE/&D^+CPO:3X@5&AE28C>#(P,3D[2X\+V9O;G0^/"]P/@T* M/'`@#L@34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H92!#;VUP86YY#0IR96-O9VYI>F5S M(')E=F5N=64@=VAE;B!E=FED96YC92!O9B!A;B!A&ES M=',L('1I=&QE#0IH87,@<&%S2!AF5D(&%T#0IT:6UE(&]F('-H:7!M96YT+B!4:&4@0V]M M<&%N>2!D;V5S(&YO="!P6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$ M14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DUA:6YT M96YA;F-E(&%N9`T*2!O=F5R('1H92!T97)M(&]F('1H92!S97)V:6-E(&-O M;G1R86-T+@T*4F5V96YU92!IF5D(&%S(&5A"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY';W9E&5D+69E90T*8F%S:7,N(%)E=F5N=65S(&9R;VT@=&AE6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/E-H87)E M+4)A6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)' M24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@'!E;G-E+"!I;F-L=61I;F<@9W)A;G1S(&]F(&5M<&QO>65E('-T;V-K(&]P M=&EO;G,L(')E'!E8W1E M9`T*9F]R9F5I='5R97,N(%1H92!F86ER('9A;'5E(&]F('-T;V-K(&]P=&EO M;B!G'!E M8W1E9"!T;R!B92!O=71S=&%N9&EN9RX\+V9O;G0^/"]P/@T*/'`@#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4 M+5-)6D4Z(#%P>"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XM M5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DUA;F%G96UE;G0-"F5S=&EM871E'!E8W1E9"!L:69E(&)A'1E;G0@:&ES=&]R:6-A;"!F;W)F96ET=7)E'!E8W1E9"!D:79I9&5N9"!Y:65L9"!O9B!Z97)O M(&ES#0IU"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@97-T:6UA=&5D#0IF86ER('9A M;'5E(&]F(&%L;"!A=V%R9',@:7,@#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CX\8CX\:3Y.97<@06-C;W5N=&EN9PT*4')O;F]U;F-E;65N=',\+VD^ M/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[ M(%1%6%0M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D9R;VT@=&EM92!T;PT*=&EM92P@;F5W(&%C8V]U;G1I;F<@<')O;F]U M;F-E;65N=',@87)E(&ES2!T:&4@1FEN86YC:6%L#0I!8V-O=6YT M:6YG(%-T86YD87)D2!T:&4@ M0V]M<&%N>2!A2!R96-E;G1L>2!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@,RX@ M1F%I2`M+3X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@ M5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@ M2!T M6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/ M33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L(#$Z(%%U;W1E9`T*;6%R:V5T('!R M:6-E6QE/3-$)TU!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@ M,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L(#(Z#0I/8G-E"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,979E;"`S.@T*56YO8G-E M#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G M/@T*/&9O;G0@&-H86YG92UT6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L(#(-"FEN M8VQU9&5S(&9I;F%N8VEA;"!I;G-T6EE;&0@8W5R=F4L('9O;&%T:6QI M='D@9F%C=&]R2!A;&P@;V8-"G1H97-E(&%S"<^#0H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,979E;"`S(&ES M#0IC;VUP6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U14 M3TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*)B-X03`[/"]P/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4-"D-O;7!A;GDF(W@R,#$Y M.W,@;6%R:V5T86)L92!S96-U6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G M/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P$$P.S(\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DQE=F5L)B-X03`[,SPO8CX\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO M='(^#0H\='(^#0H\=&0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-#X\+W1D/@T* M/'1D(&-O;'-P86X],T0T/CPO=&0^#0H\=&0@8V]LF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,30@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY!="!-87)C:"8C>$$P.S,Q+`T*,C`Q,3H\+V9O M;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@0T*6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4T+#0X,3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X- M"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)TU!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@ M,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!#;VUP86YY#0IR96-O2!A=F%I;&%B;&4N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=CX-"CQP('-T>6QE/3-$)TU! M4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@&)R;"QB;V1Y("TM/@T*/'`@"<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY4:&4@8V]M<&]N96YT6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[ M/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA!,#LS,"P\+V(^/"]F;VYT/CQBF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/BAI;@T*)FYB#(P,3D[F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY287<@;6%T97)I86QS(&%N9`T*6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#,R-3PO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`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`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T* M/'`@#L@5$585"U)3D1%3E0Z(#0E M.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2!R96-O2P@:6X@ M=W)I=&4@9&]W;G,@;V8@:6YV96YT;W)Y+"!I;F-L=61I;F<@97AC97-S#0IQ M=6%N=&ET:65S(&%N9"!O8G-O;&5T92!I;G9E;G1O6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D9R;VT@=&EM92!T M;PT*=&EM92P@=&AE($-O;7!A;GD@;&]A;G,@9FEN:7-H960@9V]O9',@:6YV M96YT;W)Y(&]N(&$@2!I M65A M2!H860-"B9N8G-P.R0P+C<@;6EL;&EO;B!I M;B!D96UO(&EN=F5N=&]R>2!A="!E86-H(&]F($IU;F4F(WA!,#LS,"P@,C`Q M,2!A;F0-"DUA2X@06UO MF%T:6]N(&5X<&5N2X\+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#-B,&5E85\S-S`T7S1D,S%? M83,Y,%\U96(Q-6-B-C,T,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO930S8C!E96%?,S'0O:'1M;#L@ M8VAA6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/CQB/DYO=&4@-2X@26YT86YG M:6)L90T*07-S971S(&%N9"!';V]D=VEL;#PO8CX\+V9O;G0^/"]P/@T*/"$M M+2!X8G)L+&)O9'D@+2T^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[ M(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/E1H92!C87)R>6EN9PT*86UO=6YT(&]F(&=O;V1W:6QL(&%T($IU;F4F M(WA!,#LS,"P@,C`Q,2!A;F0@36%R8V@F(WA!,#LS,2P@,C`Q,0T*=V%S("9N M8G-P.R0S.2XX(&UI;&QI;VX@86YD("9N8G-P.R0S."XY(&UI;&QI;VXL(')E M2P@86YD(&AA"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L#(P,3D[F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE M/3-$)U1%6%0M24Y$14Y4.B`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`@$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D)A;&%N8V4@870@ M2G5N928C>$$P.S,P+`T*,C`Q,3PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,Y+#6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO=&0^#0H\+W1R/@T*/"$M M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*/'`@#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z M(#%P>"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`P M<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!C;VUP;VYE;G1S#0IO9B!I;G1A;F=I8FQE(&%S"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA! M,#LS,"P-"C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG M;CTS1&-E;G1E$$P.S,Q+`T*,C`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`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E9A;'5E/"]B/CPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`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`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`\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+#`P-3PO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF;F)S<#LD/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C,V.3PO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS M,C,\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(Y.3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXV,CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R87`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`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXR+#,X-#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#`Q-#PO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXS-S`\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/"]T"<^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T* M/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`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`R/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B9N8G-P.R0\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ+#8S,CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X- M"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\(2TM($5N M9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XM M5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P M>"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY!;6]R=&EZ871I;VX@;V8-"FEN=&%N9VEB;&4@87-S M971S('=A$$P.S,P+"`R,#$Q(&%N9"`R,#$P M+B!4:&4@0V]M<&%N>28C>#(P,3D['!E8W1E9`T*86UOF%T:6]N M(&5X<&5N'10 M87)T7V4T,V(P965A7S,W,#1?-&0S,5]A,SDP7S5E8C$U8V(V,S0Q9@T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-#-B,&5E85\S-S`T7S1D,S%? M83,Y,%\U96(Q-6-B-C,T,68O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU4 M3U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^/&9O;G0@2`M+3X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z M(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@F5D(&EN('1H92!#;VUP86YY)B-X,C`Q.3MS#0IC;VYD96YS960@8V]N M$$P.S,P+"`R,#$Q(&%N9"`R,#$P M('=A#L@1D].5"U325I%.B`Q M,G!X)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(^#0H\ M(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H\='(^#0H\=&0@=VED=&@],T0X M,B4^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D M/@T*/'1D/CPO=&0^#0H\=&0^/"]T9#X-"CQT9#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H\=&0^/"]T9#X-"CQT9#X\ M+W1D/@T*/'1D/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.TUO;G1H$$P M.T5N9&5D/&)R("\^#0I*=6YE)B-X03`[,S`L/"]B/CPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/C(P,3`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`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E M6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4P,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS,3`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`@$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#,S,CPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF;F)S<#LD/"]F;VYT M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/"]T"<^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\(2TM($5N9"!4 M86)L92!";V1Y("TM/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XM5$]0 M.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4[($U!4D=)3BU"3U143TTZ(#!P>"<^ M#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4:&4@)FYB$$P.S,P+"`R,#$Q(&EN8VQU9&5S("9N8G-P.R0P M+CD@;6EL;&EO;B!R96QA=&5D('1O('-T;V-K#0IO<'1I;VYS(&%N9"`F;F)S M<#LD,2XT(&UI;&QI;VX@2!R96QA M=&5D('1O('!E6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H M92!R96UA:6YI;F<-"G5N$$P.S,P+"`R,#$Q('=A65A6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/E-T;V-K M#0I/<'1I;VX@06-T:79I='D\+VD^/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE. M+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E1H92!F;VQL;W=I;F<-"G1A8FQE M('-U;6UA2!F;W(@=&AE M('1H$$P.S,P+"`R,#$Q.CPO9F]N M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($U!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X-"CQT M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.RAY96%RF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/BAI;B8C>$$P.W1H;W5S M86YDF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY/=71S=&%N9&EN9R!A="!!<')I;"`Q+`T*,C`Q,3PO9F]N M=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$P+C(W/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8N,S`\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L M:6=N/3-$=&]P/@T*/'`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`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`Y/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ,2XU.3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`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`],T1N;W=R87`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`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R M/@T*/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*/'`@#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM M0D]45$]-.B`P<'@G/@T*/&9O;G0@&5R8VES960@=V%S("9N8G-P.R0U+C@@;6EL M;&EO;B!F;W(@=&AE('1H$$P.S,P M+"`R,#$Q+B!4:&4@=&]T86P@9F%I$$P.S,P M+"`R,#$Q('=A#L@34%21TE.+4)/5%1/33H@ M,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS M1"=-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/ M5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H92!#;VUP86YY#0IE#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X-"CQT86)L M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(] M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W M-B4@86QI9VX],T1C96YT97(^#0H\(2TM($)E9VEN(%1A8FQE($AE860@+2T^ M#0H\='(^#0H\=&0@=VED=&@],T0X,"4^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q."4^/"]T9#X-"CQT9#X\+W1D/@T*/"]TF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^/&9O;G0@$$P.S,P+#PO8CX\+V9O;G0^ M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@ M2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H\='(@8F=C;VQO M6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM M3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY2:7-K+69R964@:6YT97)E6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C$N.#,E/"]F;VYT M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY%>'!E8W1E9"!O<'1I;VX@;&EF90T**'EE87)S*3PO9F]N=#X\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C4Q+C8E/"]F;VYT/CPO=&0^ M#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*/'`@ M#L@5$585"U)3D1%3E0Z(#0E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2!Y M:65L9"!C=7)V92!I;B!E9F9E8W0-"F%T('1H92!T:6UE(&]F(&=R86YT(&9O M'!E8W1E9"!L:69E#0IO M9B!T:&4@2!A2!O9B!T:&4@0V]M<&%N>28C>#(P,3D[6EE M;&0@=V%S('IE"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4:&4-"G=E:6=H=&5D+6%V97)A9V4@9W)A;G0M M9&%T92!F86ER('9A;'5E(&9O6QE/3-$)TU!4D=)3BU4 M3U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/E)E"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!A9&1I=&EO;B!T;PT*"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/E1HF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P M.S,P+`T*,C`Q,3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/D9A:7(F(WA!,#M686QU93PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)U1%6%0M24Y$ M14Y4.B`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4V-#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ."XT.3PO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY697-T960\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@Q,S0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+C@X/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D9O6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/"]T"<^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`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`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M=&0^#0H\+W1R/@T*/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T* M/'`@#L@5$585"U)3D1%3E0Z(#0E M.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O&EM871E;'D@)FYBF5D(&ES#0HR+C<@ M>65A6QE/3-$)TU!4D=)3BU43U`Z(#$X M<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/E!E6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$58 M5"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY$=7)I;F<@=&AE#0IT:')E92!M;VYT:',@96YD M960@2G5N928C>$$P.S,P+"`R,#$P+"`S,3$L,#`P('-H87)E&5C=71I=F4@;V9F M:6-E#L@5$585"U)3D1%3E0Z(#0E.R!-05)' M24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@'!E;G-E('-T;V-K+6)A65A6QE/3-$)TU!4D=)3BU4 M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1U$$P.S,P M+"`R,#$Q+"!T:&4@0V]M<&%N>2!B96QI979E#L@5$585"U)3D1%3E0Z(#0E.R!-05)' M24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@F5D(&-O;7!E;G-A=&EO;@T*97AP96YS92!R96QA=&5D('1O('1H M97-E('-H87)E28C M>#(P,3D[3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]E-#-B,&5E85\S-S`T7S1D,S%?83,Y,%\U96(Q-6-B-C,T,68- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930S8C!E96%?,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R"<^/&9O;G0@&5S/"]B M/CPO9F]N=#X\+W`^#0H\(2TM('AB2`M+3X-"CQP('-T>6QE/3-$ M)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]4 M5$]-.B`P<'@G/@T*/&9O;G0@F5D(&9O"!A"!A`T*8F5N969I="!A#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]4 M5$]-.B`P<'@G/@T*/&9O;G0@`T*;&EA8FEL:71Y(&EN('1H92!A;6]U;G0@;V8@)FYB28C>#(P,3D[F5D(&]V97(@,34@>65A"!P M=7)P;W-E"!L:6%B:6QI='D@8V%N;F]T(&)E(&]F M9G-E=`T*86=A:6YS="!T:&4@0V]M<&%N>28C>#(P,3D[6QE/3-$ M)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/ M5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H92!#;VUP86YY(&%N9`T*:71S('-U M8G-I9&EA"P@87,@=V5L;"!A"!O9B!M=6QT:7!L92!S=&%T M92!A;F0@9F]R96EG;B!J=7)I0T*:&%S M(&%C8W5M=6QA=&5D('-I9VYI9FEC86YT(&QO65A"!C2!A;'-O(&)E#0IS=6)J96-T('1O(')E=FEE=R!B>2!R M96QE=F%N="!T87AI;F<@875T:&]R:71I97,@:68@=&AE(&-A7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA#L@34%21TE.+4)/5%1/33H@,'!X M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CX\8CY.;W1E(#@N($YE="!,;W-S(%!E<@T*4VAA&)R;"QB;V1Y("TM/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY"87-I8R!N970@;&]S2!P;W1E M;G1I86P@*'5N:7-S=65D*0T*#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]- M.B`P<'@G/@T*/&9O;G0@2`U+#`R-"PP,#`-"G-H87)E2`X,S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQB/DYO=&4@.2X@0V]M;6ET;65N=',@ M86YD#0I#;VYT:6YG96YC:65S/"]B/CPO9F]N=#X\+W`^#0H\(2TM('AB2`M+3X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4G/@T*/&9O;G0@6QE/3-$ M)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]4 M5$]-.B`P<'@G/@T*/&9O;G0@2!I7!E2!D:60@;F]T(&AA=F4@86YY(&UA=&5R:6%L('!E M;F1I;F<-"FQI=&EG871I;VXN/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@,3`N($%C8W)U960-"D5X<&5N2`M+3X-"CQP('-T>6QE/3-$)TU!4D=) M3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P M<'@G/@T*/&9O;G0@#L@1D].5"U325I%.B`Q,G!X M)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`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`C,#`P,#`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`],T1N;W=R87`^/&9O;G0@6QE M/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#DY M,3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#4Q.#PO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T* M/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C@L-S`P/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-"PP-S@\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]E-#-B,&5E85\S-S`T7S1D,S%?83,Y,%\U M96(Q-6-B-C,T,68-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930S M8C!E96%?,S'0O:'1M;#L@8VAA6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO M=&4@,3$N(%-E9VUE;G0@86YD#0I%;G1E&)R;"QB;V1Y("TM/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>0T*;W!E2!P87)T(&]F('1H92!#;VUP86YY('-E<&%R871E;'DL(&%N9"!T:&4@ M86QL;V-A=&EO;@T*;V8@2X@4F5M86EN:6YG(&%S0T*28C M>#(P,3D[$$P M.S,P+"`R,#$Q(&%N9"!-87)C:"8C>$$P.S,Q+"`R,#$Q+"!R97-P96-T:79E M;'DN(%1O=&%L#0IA$$P.S,Q+"`R,#$Q+B!& M;W(@96%C:"!O9B!T:&4@=&AR964@;6]N=&AS(&5N9&5D#0I*=6YE)B-X03`[ M,S`L(#(P,3$@86YD(#(P,3`L(&EN=&5R;F%T:6]N86P@'1087)T7V4T,V(P965A7S,W,#1?-&0S,5]A,SDP7S5E8C$U8V(V,S0Q9@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-#-B,&5E85\S-S`T7S1D M,S%?83,Y,%\U96(Q-6-B-C,T,68O5V]R:W-H965T'1087)T7V4T F,V(P965A7S,W,#1?-&0S,5]A,SDP7S5E8C$U8V(V,S0Q9BTM#0H` ` end

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands	3 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands	Jun. 30, 2011	Jun. 30, 2010
Operating activities:
Net loss	$ (4,594)	$ (5,980)
Adjustments required to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	1,046	959
Bad debt expense	15	53
Stock-based compensation	2,332	1,371
Write-down of inventory	156	623
Loss on disposal of fixed assets		5
Deferred tax provision	96	243
Gain on sale of WorldHeart common stock		(239)
Changes in assets and liabilities source (use):
Accounts receivable	847	767
Inventories	(1,601)	645
Prepaid expenses and other current assets	220	292
Accounts payable	(1,360)	705
Accrued expenses	(5,443)	(2,169)
Deferred revenue	(270)	78
Net cash used for operating activities	(8,556)	(2,647)
Investing activities:
Purchases of short-term marketable securities	(5,001)	(1,501)
Proceeds from the sale and maturity of short-term marketable securities	4,500	4,000
Proceeds from the sale of WorldHeart common stock		239
Expenditures for property and equipment	(472)	(289)
Net cash (used in) provided by investing activities	(973)	2,449
Financing activities:
Proceeds from the exercise of stock options	7,629	94
Net cash provided by financing activities	7,629	94
Effect of exchange rate changes on cash	220	(743)
Net decrease in cash and cash equivalents	(1,680)	(847)
Cash and cash equivalents at beginning of period	5,831	4,788
Cash and cash equivalents at end of period	4,151	3,941
Supplemental disclosure:
Fixed asset additions included in accounts payable	$ 44	$ 31

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands	Jun. 30, 2011	Mar. 31, 2011
Current assets:
Cash and cash equivalents	$ 4,151	$ 5,831
Short-term marketable securities	54,982	54,481
Accounts receivable, net	14,541	15,376
Inventories	8,879	7,505
Prepaid expenses and other current assets	1,339	1,544
Total current assets	83,892	84,737
Property and equipment, net	6,214	6,273
Intangible assets, net	1,279	1,632
Goodwill	39,752	38,946
Total assets	131,137	131,588
Current liabilities:
Accounts payable	4,964	6,283
Accrued expenses	8,700	14,078
Deferred revenue	1,715	1,982
Total current liabilities	15,379	22,343
Long-term deferred tax liability	4,106	4,010
Other long-term liabilities	469	492
Total liabilities	19,954	26,845
Commitments and contingencies (Note 9)
Stockholders' equity:
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 38,560,747 shares at June 30, 2011 and 37,756,719 shares at March 31, 2011; Outstanding - 38,509,793 shares at June 30, 2011 and 37,705,765 shares at March 31, 2011	385	377
Additional paid-in-capital	389,217	379,218
Accumulated deficit	(279,364)	(274,770)
Treasury stock at cost - 50,954 shares	(827)	(827)
Accumulated other comprehensive income	1,772	745
Total stockholders' equity	111,183	104,743
Total liabilities and stockholders' equity	$ 131,137	$ 131,588